Document and Entity Information
Document and Entity Information - shares | 6 Months Ended | |
Jun. 30, 2017 | Jul. 25, 2017 | |
Document and Entity Information | ||
Entity Registrant Name | AMICUS THERAPEUTICS INC | |
Entity Central Index Key | 1,178,879 | |
Document Type | 10-Q | |
Document Period End Date | Jun. 30, 2017 | |
Amendment Flag | false | |
Current Fiscal Year End Date | --12-31 | |
Entity Current Reporting Status | Yes | |
Entity Filer Category | Large Accelerated Filer | |
Entity Common Stock, Shares Outstanding | 164,566,069 | |
Document Fiscal Year Focus | 2,017 | |
Document Fiscal Period Focus | Q2 |
Consolidated Balance Sheets
Consolidated Balance Sheets - USD ($) $ in Thousands | Jun. 30, 2017 | Dec. 31, 2016 |
Current assets: | ||
Cash and cash equivalents | $ 37,394 | $ 187,026 |
Investments in marketable securities | 189,838 | 143,325 |
Accounts receivable | 3,786 | 1,304 |
Inventories | 3,948 | 3,416 |
Prepaid expenses and other current assets | 6,023 | 4,993 |
Total current assets | 240,989 | 340,064 |
Property and equipment, less accumulated depreciation of $ 13,951 and $12,495 at June 30, 2017 and December 31, 2016, respectively | 10,471 | 9,816 |
In-process research & development | 486,700 | 486,700 |
Goodwill | 197,797 | 197,797 |
Other non-current assets | 3,009 | 2,468 |
Total Assets | 938,966 | 1,036,845 |
Current liabilities: | ||
Accounts payable, accrued expenses , and other current liabilities | 35,645 | 41,008 |
Deferred reimbursements, current portion | 18,850 | 13,850 |
Contingent consideration payable, current portion | 46,188 | 56,101 |
Total current liabilities | 100,683 | 110,959 |
Deferred reimbursements | 16,906 | 21,906 |
Convertible notes | 159,171 | 154,464 |
Contingent consideration payable | 219,162 | 213,621 |
Deferred income taxes | 173,869 | 173,771 |
Other non-current liability | 2,283 | 1,973 |
Commitments and contingencies | ||
Stockholders' equity: | ||
Common stock, $0.01 par value, 250,000,000 shares authorized,143,371,243 and 142,691,986 shares issued and outstanding at June 30, 2017 and December 31, 2016, respectively | 1,485 | 1,480 |
Additional paid-in capital | 1,132,229 | 1,120,156 |
Accumulated other comprehensive loss: | ||
Foreign currency translation adjustment, less tax expense of $1,293 at June 30, 2017 and December 31, 2016 | (192) | 1,945 |
Unrealized gain on available-for securities | 31 | 102 |
Warrants | 16,076 | 16,076 |
Accumulated deficit | (882,737) | (779,608) |
Total stockholders' equity | 266,892 | 360,151 |
Total Liabilities and Stockholders' Equity | $ 938,966 | $ 1,036,845 |
Consolidated Balance Sheets (Pa
Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands | 6 Months Ended | 12 Months Ended |
Jun. 30, 2017 | Dec. 31, 2016 | |
Consolidated Balance Sheets | ||
Accumulated depreciation of property and equipment (in dollars) | $ 13,951 | $ 12,495 |
Common stock, par value (in dollars per share) | $ 0.01 | $ 0.01 |
Common stock, shares authorized | 250,000,000 | 250,000,000 |
Common stock, shares issued | 143,371,243 | 142,691,986 |
Common stock, shares outstanding | 143,371,243 | 142,691,986 |
Foreign currency translation adjustment, tax expense | $ 1,293 | $ 1,293 |
Consolidated Statements of Oper
Consolidated Statements of Operations - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2017 | Jun. 30, 2016 | Jun. 30, 2017 | Jun. 30, 2016 | |
Revenue: | ||||
Net product sales | $ 7,158 | $ 11,327 | ||
Cost of goods sold | 1,061 | 1,836 | ||
Gross Profit | 6,097 | 9,491 | ||
Operating Expenses: | ||||
Research and development | 31,985 | $ 18,281 | 62,861 | $ 41,706 |
Selling, general and administrative | 19,311 | 19,300 | 38,443 | 35,001 |
Changes in fair value of contingent consideration payable | 1,050 | 10,186 | 5,628 | 13,338 |
Restructuring charges | 8 | 58 | ||
Depreciation | 812 | 767 | 1,636 | 1,440 |
Total operating expenses | 53,158 | 48,542 | 108,568 | 91,543 |
Loss from operations | (47,061) | (48,542) | (99,077) | (91,543) |
Other income (expenses): | ||||
Interest income | 753 | 331 | 1,512 | 638 |
Interest expense | (4,179) | (1,055) | (8,469) | (2,000) |
Other income (expense) | 2,400 | (2,237) | 3,010 | (2,289) |
Loss before income tax (expense)/benefit | (48,087) | (51,503) | (103,024) | (95,194) |
Income tax (expense)/ benefit | (49) | 453 | (105) | 453 |
Net loss attributable to common stockholders | $ (48,136) | $ (51,050) | $ (103,129) | $ (94,741) |
Net loss attributable to common stockholders per common share - basic and diluted | $ (0.34) | $ (0.40) | $ (0.72) | $ (0.75) |
Weighted-average common shares outstanding - basic and diluted | 143,000,718 | 129,122,175 | 142,886,614 | 127,160,943 |
Consolidated Statements of Comp
Consolidated Statements of Comprehensive Loss - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2017 | Jun. 30, 2016 | Jun. 30, 2017 | Jun. 30, 2016 | |
Consolidated Statements of Comprehensive Loss | ||||
Net loss | $ (48,136) | $ (51,050) | $ (103,129) | $ (94,741) |
Other comprehensive (loss)/ gain: | ||||
Foreign currency translation adjustment (loss)/ gain | (1,678) | 907 | (2,136) | 842 |
Unrealized (loss)/ gain on available-for-sale securities | (155) | 87 | (72) | 316 |
Other comprehensive (loss)/income | (1,833) | 994 | (2,208) | 1,158 |
Comprehensive loss | $ (49,969) | $ (50,056) | $ (105,337) | $ (93,583) |
Consolidated Statements of Cash
Consolidated Statements of Cash Flows - USD ($) $ in Thousands | 6 Months Ended | |
Jun. 30, 2017 | Jun. 30, 2016 | |
Operating activities | ||
Net loss | $ (103,129) | $ (94,741) |
Adjustments to reconcile net loss to net cash used in operating activities: | ||
Non-cash interest expense | 4,715 | 1,014 |
Depreciation | 1,636 | 1,440 |
Stock-based compensation | 11,567 | 8,748 |
Restructuring charges | 58 | |
(Gain)/ Loss on disposal of asset | (8) | 17 |
Change in fair value of derivative liability | (265) | 346 |
Non-cash changes in the fair value of contingent consideration payable | 5,628 | 13,338 |
Foreign currency remeasurement loss | (3,003) | 1,892 |
Non-cash income tax benefit | (453) | |
Non-cash deferred taxes | 98 | |
Changes in operating assets and liabilities: | ||
Accounts receivable | (2,226) | |
Inventories | (351) | (207) |
Prepaid expenses and other current assets | (2,103) | (865) |
Other non-current assets | (521) | (549) |
Account payable and accrued expenses | (4,297) | (8,244) |
Non-current liabilities | 496 | 535 |
Net cash used in operating activities | (91,763) | (77,671) |
Investing activities | ||
Sale and redemption of marketable securities | 137,909 | 121,283 |
Purchases of marketable securities | (184,494) | (126,914) |
Purchases of property and equipment | (2,279) | (4,608) |
Net cash used in investing activities | (48,864) | (10,239) |
Financing activities | ||
Proceeds from issuance of common stock, net of issuance costs | 57,818 | |
Proceeds from unsecured loan agreement | 30,000 | |
Payment of capital leases | (142) | (47) |
Payment of contingent consideration | (10,000) | (5,000) |
Purchase of vested restricted stock units | (1,003) | (657) |
Proceeds from exercise of stock options | 1,554 | 647 |
Payment of deferred financing fees | (28) | |
Net cash used in / (provided by) financing activities | (9,619) | 82,761 |
Effect of exchange rate changes on cash and cash equivalents | 614 | (680) |
Net decrease in cash and cash equivalents | (149,632) | (5,829) |
Cash and cash equivalents at beginning of year/ period | 187,026 | 69,485 |
Cash and cash equivalents at end of year/period | 37,394 | 63,656 |
Supplemental disclosures of cash flow information | ||
Cash paid during the period for interest | 3,650 | 276 |
Contingent consideration resolution in shares | 6,115 | |
Capital expenditures unpaid at the end of the period | $ 351 | |
Capital expenditures funded by capital lease borrowings | $ 850 |
Description of Business
Description of Business | 6 Months Ended |
Jun. 30, 2017 | |
Description of Business | |
Description of Business | Note 1. Description of Business Corporate Information, Status of Operations, and Management Plans Amicus Therapeutics, Inc. (the “Company”) is a global patient-focused biotechnology company engaged in the discovery, development and commercialization of a diverse set of novel treatments for patients living with devastating rare and orphan diseases. The Company’s lead product, migalastat HCl, is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (“ERT”) for Fabry disease. Migalastat was approved for use in the European Union (“EU”) in May 2016 under the brand name Galafold™ as a first-line therapy for long-term treatment of adults and adolescents aged 16 years and older with a confirmed diagnosis of Fabry disease and who have an amenable mutation. Additionally, based on a series of discussions with and written communication received from the U.S. Food and Drug Administration (the “FDA”), the FDA has informed the Company that it may now submit a New Drug Application (“NDA”) for migalastat. An additional Phase 3 study previously requested by the FDA to assess Gastrointestinal (“GI”) symptoms is no longer required before an NDA submission. The Company is preparing the NDA submission under Subpart H, which provides for accelerated approval and plan to submit an NDA to the FDA for migalastat for Fabry disease in the fourth quarter of 2017. Also in the pipeline, SD-101 is a product candidate in late-stage development, as a potential first-to-market therapy for the chronic, rare connective tissue disorder Epidermolysis Bullosa (“EB”). On May 31, 2017, SD-101 received Rare Pediatric Disease designation from the FDA. The FDA grants Rare Pediatric Disease designation for diseases that primarily affect children ages 18 years or younger and fewer than 200,000 persons in the U.S. We are also developing ATB200/AT2221, a novel treatment paradigm for Pompe disease that consists of a unique recombinant enzyme co-administered with AT2221, a pharmacological chaperone. The Company may further leverage its Chaperone-Advanced Replacement Therapy (“CHART™”) platform technologies to develop novel ERT products for other lysosomal storage disorders (“LSDs”). The Company is also investigating preclinical and discovery programs in other rare and devastating diseases including cyclin-dependent kinase-like 5 (“CDKL5”) deficiency. The Company believes that its platform technologies and its product pipeline uniquely position it at the forefront of advanced therapies to treat a range of devastating rare and orphan diseases. On July 12, 2017, the Company entered into an underwriting agreement (“the Underwriting Agreement”) with J.P. Morgan Securities LLC and Goldman Sachs & Co. LLC, as representatives of the several underwriters set forth on Schedule 1 thereto, relating to an underwritten public offering of the Company’s common stock (the “Offering”). Under the terms of the Underwriting Agreement, the Company issued and sold 21,122,449 shares at a price to the public of $12.25 per share, resulting in gross proceeds of $258.8 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by the Company. The Offering closed on July 18, 2017 and the Company received net proceeds from the Offering, after deducting underwriting discounts and commissions and offering expenses payable by the Company of $243.2 million. See “ — Note 12 Subsequent Events” for more details. The Company believes that its existing cash and cash equivalents and short-term investments will be sufficient to fund the current operating plan into the second half of 2019. |
Summary of Significant Accounti
Summary of Significant Accounting Policies | 6 Months Ended |
Jun. 30, 2017 | |
Summary of Significant Accounting Policies | |
Summary of Significant Accounting Policies | Note 2. Summary of Significant Accounting Policies Basis of Presentation The Company has prepared the accompanying unaudited consolidated financial statements in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10-01 of Regulation S-X. Accordingly, they do not include all of the information and disclosures required by U.S. GAAP for complete financial statements. In the opinion of management, the accompanying unaudited financial statements reflect all adjustments, which include only normal recurring adjustments, necessary to present fairly the Company’s interim financial information. The accompanying unaudited consolidated financial statements and related notes should be read in conjunction with the Company’s financial statements and related notes as contained in the Company’s Annual Report on Form 10-K, as amended, for the year ended December 31, 2016. For a complete description of the Company’s accounting policies, please refer to the Annual Report on Form 10-K, as amended for the year ended December 31, 2016. Consolidation The consolidated financial statements include the accounts of the Company and its subsidiaries. Intercompany accounts and transactions have been eliminated in consolidation. Foreign Currency Transactions The functional currency for most of the Company’s foreign subsidiaries is their local currency. For non-U.S. subsidiaries that transact in a functional currency other than the U.S. dollar, assets and liabilities are translated at current rates of exchange at the balance sheet date. Income and expense items are translated at the average foreign exchange rates for the period. Adjustments resulting from the translation of the financial statements of the Company’s foreign operations into U.S. dollars are excluded from the determination of net income and are recorded in accumulated other comprehensive income, a separate component of stockholders’ equity. The Company transacts business in various foreign countries and therefore, is subject to risk of foreign currency exchange rate fluctuations. As such, in June 2016, the Company entered into a forward contract to economically hedge transactional exposure associated with commitments arising from trade accounts payable denominated in a currency other than the functional currency of the respective operating entity. The Company does not designate this forward contract as a hedging instrument under applicable accounting guidance and, therefore, changes in fair value are recorded as other expense in the Consolidated Statements of Operations. The forward contract expired in June 2017. Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates. Concentration of Credit Risk The Company’s financial instruments that are exposed to concentration of credit risk consist primarily of cash and cash equivalents and marketable securities. The Company maintains its cash and cash equivalents in bank accounts, which, at times, exceed federally insured limits. The Company invests its marketable securities in high-quality commercial financial instruments. The Company has not recognized any losses from credit risks on such accounts during any of the periods presented. The Company believes it is not exposed to significant credit risk on cash and cash equivalents or its marketable securities. The Company is subject to credit risk from its accounts receivable related to its product sales of Galafold™. The majority of the Company’s accounts receivable at June 30, 2017 have arisen from product sales in Germany. The Company will periodically assess the financial strength of its customers to establish allowances for anticipated losses, if any. For accounts receivable that have arisen from named patient sales, the payment terms are predetermined and the Company evaluates the creditworthiness of each customer on a regular basis. To date, the Company has not incurred any credit losses. Significant Accounting Policies There have been no material changes to the Company’s significant accounting policies during the six months ended June 30, 2017, as compared to the significant accounting policies disclosed in Note 2 of the Consolidated Financial Statements in the Company’s Annual Report on Form 10-K, as amended, for the year ended December 31, 2016. However, the following accounting policies are the most critical in fully understanding and evaluating the Company’s financial condition and results of operations. Revenue Recognition The Company recognizes revenue when amounts are realized or realizable and earned. Revenue is considered realizable and earned when persuasive evidence of an arrangement exists, title to product and associated risk of loss has passed to the customer, which is typically upon receipt by the end customer, the price is fixed or determinable, collection of the amounts due are reasonably assured and the Company has no further performance obligations. The Company’s net product sales consist solely of sales of Galafold™ for the treatment of Fabry disease in the EU. The Company has recorded revenue on sales where Galafold™ is available either on a commercial basis or through a reimbursed early access program. Orders for Galafold™ are generally received from pharmacies and the ultimate payor is typically a government authority. The Company records revenue net of estimated third party discounts and rebates. Allowances are recorded as a reduction of revenue at the time revenues from product sales are recognized. These allowances are adjusted to reflect known changes in factors and may impact such allowances in the quarter those changes are known. Allowance as of June 30, 2017 are immaterial. Inventories and Cost of Goods Sold Prior to regulatory approval of Galafold™, the Company expensed all manufacturing costs related to Galafold™ as research and development expense. Upon regulatory approval, the Company began capitalizing costs related to the purchase and manufacture of Galafold™. Inventories are stated at the lower of cost and net realizable value, determined by the first-in, first-out method. Inventories are reviewed periodically to identify slow-moving or obsolete inventory based on projected sales activity as well as product shelf-life. In evaluating the recoverability of inventories produced, the probability that revenue will be obtained from the future sale of the related inventory is considered and inventory value is written down for inventory quantities in excess of expected requirements. Expired inventory is disposed of and the related costs are recognized as cost of product sales in the consolidated statements of operations. Cost of goods sold includes the cost of inventory sold, manufacturing and supply chain costs, product shipping and handling costs, provisions for excess and obsolete inventory, as well as royalties payable. A portion of the inventory available for sale was expensed as research and development costs prior to regulatory approval and as such the cost of goods sold and related gross margins are not necessarily indicative of future cost of goods sold and gross margin. Fair Value Measurements The Company records certain asset and liability balances under the fair value measurements as defined by the FASB guidance. Current FASB fair value guidance emphasizes that fair value is a market-based measurement, not an entity-specific measurement. Therefore, a fair value measurement should be determined based on the assumptions that market participants would use in pricing the asset or liability. As a basis for considering market participant assumptions in fair value measurements, current FASB guidance establishes a fair value hierarchy that distinguishes between market participant assumptions based on market data obtained from sources independent of the reporting entity (observable inputs that are classified within Levels 1 and 2 of the hierarchy) and the reporting entity’s own assumptions that market participants assumptions would use in pricing assets or liabilities (unobservable inputs classified within Level 3 of the hierarchy). Level 1 inputs utilize quoted prices (unadjusted) in active markets for identical assets or liabilities that the Company has the ability to access at measurement date. Level 2 inputs are inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly. Level 2 inputs may include quoted prices for similar assets and liabilities in active markets, as well as inputs that are observable for the asset or liability (other than quoted prices), such as interest rates, foreign exchange rates, and yield curves that are observable at commonly quoted intervals. Level 3 inputs are unobservable inputs for the asset or liability, which is typically based on an entity’s own assumptions, as there is little, if any, related market activity. In instances where the determination of the fair value measurement is based on inputs from different levels of the fair value hierarchy, the level in the fair value hierarchy within which the entire fair value measurement falls is based on the lowest level input that is significant to the fair value measurement in its entirety. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment, and considers factors specific to the asset or liability. Contingent Liabilities On an ongoing basis, the Company may be involved in various claims, and legal proceedings. On a quarterly basis, the Company reviews the status of each significant matter and assesses its potential financial exposure. If the potential loss from any claim, asserted or unasserted, or legal proceeding is considered probable and the amount can be reasonably estimated, the Company will accrue a liability for the estimated loss. Because of uncertainties related to claims and litigation, accruals will be based on the Company’s best estimates based on available information. On a periodic basis, as additional information becomes available, or based on specific events such as the outcome of litigation or settlement of claims, the Company may reassess the potential liability related to these matters and may revise these estimates, which could result in material adverse adjustments to the Company’s operating results. Recent Accounting Pronouncements In July 2017, the FASB issued ASU 2017-11, Earnings Per Share (Topic 260); Distinguishing Liabilities from Equity (Topic 480); Derivatives and Hedging (Topic 815): (Part I) Accounting for Certain Financial Instruments with Down Round Features, (Part II) Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception . Part I of this Update addresses the complexity of accounting for certain financial instruments with down round features. Down round features are features of certain equity-linked instruments (or embedded features) that result in the strike price being reduced on the basis of the pricing of future equity offerings. When determining whether certain financial instruments should be classified as liabilities or equity instruments, a down round feature no longer precludes equity classification when assessing whether the instrument is indexed to an entity’s own stock. Part II of this Update addresses the difficulty of navigating Topic 480, Distinguishing Liabilities from Equity, because of the existence of extensive pending content in the FASB Accounting Standards Codification®. For public business entities, the amendments in Part I of this Update are effective for fiscal years, and years, beginning after December 15, 2018. Early adoption is permitted for all entities, including adoption in an interim period. The Company is currently assessing the impact that this standard will have on its consolidated financial statements. In May 2017, the FASB issued ASU 2017-09, Compensation—Stock Compensation (Topic 718): Scope of Modification Accounting . The amendments provide guidance on determining which changes to the terms and conditions of share-based payment awards require an entity to apply modification accounting under Topic 718 Compensation—Stock Compensation. An entity should account for the effects of a modification unless all the following are met: 1. The fair value (or calculated value or intrinsic value, if such an alternative measurement method is used) of the modified award is the same as the fair value (or calculated value or intrinsic value, if such an alternative measurement method is used) of the original award immediately before the original award is modified. If the modification does not affect any of the inputs to the valuation technique that the entity uses to value the award, the entity is not required to estimate the value immediately before and after the modification. 2. The vesting conditions of the modified award are the same as the vesting conditions of the original award immediately before the original award is modified. 3. The classification of the modified award as an equity instrument or a liability instrument is the same as the classification of the original award immediately before the original award is modified. The ASU is effective for all entities for annual periods, including interim periods within those annual periods, beginning after December 15, 2017. Early adoption is permitted, including adoption in any interim period. The Company is currently assessing the impact that this standard will have on its consolidated financial statements. In March 2017, the FASB issued ASU 2017-08, Receivables—Nonrefundable Fees and Other Costs (Subtopic 310-20), Premium Amortization on Purchased Callable Debt Securities. The amendments shorten the amortization period for certain callable debt securities held at a premium. Specifically, the amendments require the premium to be amortized to the earliest call date. The amendments do not require an accounting change for securities held at a discount; the discount continues to be amortized to maturity. The ASU is effective for public business entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. For other entities, the amendments are effective for fiscal years beginning after December 15, 2019, and interim periods within fiscal years beginning after December 15, 2020. Early adoption is permitted, including adoption in an interim period. If an entity early adopts in an interim period, any adjustments should be reflected as of the beginning of the fiscal year that includes that interim period. The amendments should be applied on a modified retrospective basis, with a cumulative-effect adjustment directly to retained earnings as of the beginning of the period of adoption. The Company is currently assessing the impact that this standard will have on its consolidated financial statements. In January 2017, the FASB issued ASU 2017-04, Intangibles - Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment . To simplify the subsequent measurement of goodwill, ASU 2017-04 eliminates Step 2 from the goodwill impairment test. The annual, or interim, goodwill impairment test is performed by comparing the fair value of a reporting unit with its carrying amount. An impairment charge should be recognized for the amount by which the carrying amount exceeds the reporting unit’s fair value; however, the loss recognized should not exceed the total amount of goodwill allocated to that reporting unit. In addition, income tax effects from any tax deductible goodwill on the carrying amount of the reporting unit should be considered when measuring the goodwill impairment loss, if applicable. ASU 2017-04 also eliminates the requirements for any reporting unit with a zero or negative carrying amount to perform a qualitative assessment and, if it fails that qualitative test, to perform Step 2 of the goodwill impairment test. An entity still has the option to perform the qualitative assessment for a reporting unit to determine if the quantitative impairment test is necessary. ASU 2017-04 should be applied on a prospective basis. The nature of and reason for the change in accounting principle should be disclosed upon transition. A public business entity that is a U.S. SEC filer should adopt ASU 2017-04 for its annual or any interim goodwill impairment tests in fiscal years beginning after December 15, 2019. Early adoption is permitted for interim or annual goodwill impairment tests performed on testing dates after January 1, 2017. The Company is currently assessing the impact that this standard will have on its consolidated financial statements. In January 2017, the FASB issued ASU 2017-01, Business Combinations (Topic 805): Clarifying the Definition of a Business. This Accounting Standards Update clarifies the definition of a business. The amendments affect all companies and other reporting organizations that must determine whether they have acquired or sold a business. The amendments in this update are effective for public companies for annual periods beginning after December 15, 2017, including interim periods within those periods. Early adoption is permitted under certain circumstances. The amendments should be applied prospectively as of the beginning of the period of adoption. The Company is currently assessing the impact that this standard will have on its consolidated financial statements. In October 2016, the FASB issued ASU 2016-16, Income Taxes (Topic 740): Intra-Entity Transfers of Assets Other Than Inventory . This Accounting Standards Update requires an entity to recognize the income tax consequences of an intra-entity transfer of an asset other than inventory when the transfer occurs. The amendments eliminate the exception for an intra-entity transfer of an asset other than inventory. The amendments in this Update are effective for public business entities for annual periods beginning after December 15, 2017, including interim reporting periods within those annual reporting periods. Early adoption is permitted for all entities in the first interim period if an entity issues interim financial statements. The Company is currently assessing the impact that this standard will have on its consolidated financial statements. The Company has not completed review of the impact of this guidance and does not expect this new guidance to have a material impact on its consolidated financial statements. In March 2016, the FASB issued ASU 2016-09, Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting . The amendments are intended to improve the accounting for employee share-based payments and affect all organizations that issue share-based payment awards to their employees. Several aspects of the accounting for share-based payment award transactions are simplified, including: (a) income tax consequences; (b) classification of awards as either equity or liabilities; and (c) classification on the statement of cash flows. For public companies, the amendments are effective for annual periods beginning after December 15, 2016, and interim periods within those annual periods. The Company adopted ASU 2016-09 on January 1, 2017. Due to the Company’s history of operating losses, the adoption did not result in changes to the Company’s Net loss or Retained earnings and the classification of excess tax benefits on the statement of cash flows for prior periods have not been adjusted. In connection with the adoption of ASU 2016-9, the Company made a policy election to continue its methodology for the development and application of its forfeiture rate. In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842) . This update requires the recognition of lease assets and lease liabilities on the balance sheet for all lease obligations and disclosing key information about leasing arrangements. This update requires the recognition of lease assets and lease liabilities by lessees for those leases classified as operating leases under previous generally accepted accounting principles. This update will be effective for the Company for all annual and interim periods beginning after December 15, 2018, including interim periods within those fiscal years. Early application is permitted for all public business entities and all nonpublic business entities upon issuance. The Company is currently assessing the impact that this standard will have on its consolidated financial statements. In May 2014, FASB issued ASU 2014-09, Revenue from Contracts with Customers which along with amendments issued in 2015 and 2016, will replace substantially all current US GAAP guidance on this topic and eliminate industry-specific guidance. ASU 2014-09 also requires additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to obtain or fulfill a contract. The guidance permits two methods of adoption: full retrospective method (retrospective application to each prior reporting period presented) or modified retrospective method (retrospective application with the cumulative effect of initially applying the guidance recognized at the date of initial application and providing certain additional disclosures). ASU 2014-09 will become effective for the Company during the first quarter of 2018. The Company continues to assess the impact of ASU 2014-09 on its business and financial statements and expects the adoption of ASU 2014-09 to have an impact to its financial reporting disclosures and internal controls over financial reporting (“ICFR”). The Company has developed implementation controls that allow the Company to properly and timely adopt the new revenue accounting standard on its effective date. The Company will make continuous updates to the quarterly and year-end disclosures, with a focus on both status and internal controls over financial reporting. The Company’s implementation plan includes a phased implementation project plan, an understanding of the new standard and its requirements, assessment of the Company’s revenue streams and specific contracts in the streams. Additionally, the Company continues to monitor modifications, clarifications and interpretations issued by the FASB that may impact its assessment. Upon completion of the Company’s implementation plan and evaluation of the remaining revenue contracts, the Company plans to adopt additional internal controls over financial reporting for any new revenue arrangements. The Company is on target to complete its assessment of ASU 2014-09 and the impact on the Company’s consolidated financial statements and related disclosures as of January 1, 2018. The Company has elected to adopt the new standard using the modified retrospective approach. |
Acquisitions
Acquisitions | 6 Months Ended |
Jun. 30, 2017 | |
Acquisitions | |
Acquisitions | 3. Acquisitions Asset acquisition of MiaMed, Inc. In July 2016, the Company entered into an Agreement and Plan of Merger (the “MiaMed Agreement”) with MiaMed, Inc., (“MiaMed”). MiaMed is a pre-clinical biotechnology company focused on developing protein replacement therapy for CDKL5 and related diseases. Under the terms of the MiaMed Agreement, the former holders of MiaMed’s capital stock received an aggregate of $6.5 million, comprised of (i) approximately $1.8 million in cash (plus MiaMed’s cash and cash equivalents at closing and less any of MiaMed’s unpaid third-party fees and expenses related to the transaction), and (ii) 825,603 shares of the Company’s common stock, par value $0.01 per share (“Common Stock”). In addition, the Company also agreed to pay up to an additional $83.0 million in connection with the achievement of certain clinical, regulatory and commercial milestones, for a potential aggregate deal value of $89.5 million. The Company evaluated the transaction based on the guidance of Accounting Standard Codification (“ASC”) 805 , Business Combinations and concluded that it only acquired inputs and did not acquire any processes. The Company will need to develop its own processes in order to produce an output. Therefore, the Company accounted for the transaction as an asset acquisition and accordingly $6.5 million was expensed to research and development. Acquisition of Scioderm, Inc. In September 2015, the Company acquired Scioderm Inc., (“Scioderm”), a privately-held biopharmaceutical company focused on developing innovative therapies for treating the rare disease EB. The acquisition leverages the Scioderm development team’s EB expertise with the Company’s global clinical infrastructure to advance SD-101 toward regulatory approvals and the Company’s commercial, patient advocacy, and medical affairs infrastructure to support a successful global launch. The acquisition of Scioderm was accounted for as a purchase of a business in accordance with ASC 805 Business Combinations . The Company acquired Scioderm in a cash and stock transaction. At closing, the Company paid Scioderm shareholders, option holders, and warrant holders approximately $223.9 million, of which approximately $141.1 million was paid in cash and approximately $82.8 million was paid through the issuance of approximately 5.9 million newly issued shares of the Company’s Common Stock. The Company has agreed to pay up to an additional $361 million to Scioderm shareholders, option holders and warrant holders upon achievement of certain clinical and regulatory milestones, and $257 million to Scioderm shareholders, option holders, and warrant holders upon achievement of certain sales milestones. If SD-101 is approved, EB qualifies as a rare pediatric disease under The Food and Drug Administration Safety and Innovation Act (“FDSIA”) and the Company will request a Priority Review Voucher (“PRV”) under the FDSIA, if available. If the PRV is obtained and subsequently sold, the Company will pay Scioderm shareholders, option holders, and warrant holders the lesser of $100 million in the aggregate or 50% of the proceeds of such sale. If the Company obtains the PRV and has not entered into an agreement to sell or otherwise transfer to a third party the PRV within one year of its receipt, the shareholders ‘agent may appoint a financial advisor to conduct a process to sell the PRV. If the Company determines in its sole discretion to use the PRV, the Company shall give the shareholders’ agent written notice thereof and shall pay to the Scioderm shareholders, option holders, and warrant holders $100 million. The inability to sell the PRV after complying with the provisions, shall not give rise to any payment. The fair value of the contingent consideration payments on the acquisition date was $259.0 million. This was an estimate based on significant inputs that are not observable in the market, referred to as Level 3 inputs. Key assumptions included a range of discount rates between 0.4% and 1.1% as interpolated from the U.S. Treasury constant maturity yield curve over the time frame for clinical and regulatory milestones and a range of discount rates between 1.0% and 2.2% for revenue-based milestones. The range of outcomes and assumptions used to develop these estimates have been updated to better reflect the probability of certain milestone outcomes and updated timelines related to clinical development and anticipated approval assumptions as of June 30, 2017, without limitation, the milestone payments projected for 2017 (See “— Note 9. Assets and Liabilities Measured at Fair Value”, for additional discussion regarding fair value measurements of the contingent acquisition consideration payable). In April 2016, while the total clinical and regulatory approval milestone payments remained unchanged at $361 million, the allocation between the clinical and regulatory approval milestone payments was revised as follows: clinical milestones of up to $81 million and regulatory approval milestones of up to $280 million. The commercial milestone payments of up to $257 million remained unchanged. At the end of the first quarter of 2017, the Company achieved 100% enrollment in the Phase 3 clinical study of SD-101 and the milestone payment of $10 million due for this event, was paid in April 2017. The Company determined the fair value of the contingent consideration to be $254.7 million at June 30, 2017, of which $46.2 million is payable in the next twelve months, resulting in an increase in the contingent consideration payable and related expense of approximately $0.7 million for the three months ended June 30, 2017. The expense is recorded in the Consolidated Statement of Operations as the change within fair value of contingent consideration payable. Acquisition of Callidus Biopharma, Inc. In November 2013, the Company acquired Callidus a privately-held biologics company focused on developing best-in-class ERTs for LSDs with its lead ERT ATB200 for Pompe disease in late preclinical development. The acquisition of the Callidus assets and technology complements Amicus’ CHART™ platform for the development of next generation ERTs. For additional information, see “— Note 4. Goodwill and Intangible Assets.” |
Goodwill and IPR&D
Goodwill and IPR&D | 6 Months Ended |
Jun. 30, 2017 | |
Goodwill and IPR&D | |
Goodwill and IPR&D | 4. Goodwill and IPR&D In connection with the acquisitions, the Company has recognized goodwill of $197.8 million. The following table represents the changes in goodwill for the six months ended June 30, 2017: (in millions) Balance at December 31, 2016 $ Change in goodwill — Balance at June 30, 2017 $ In connection with the acquisitions, the Company recognized IPR&D of $486.7 million. Intangible assets related to IPR&D assets are considered to be indefinite-lived until the completion or abandonment of the associated research and development efforts. During the period the assets are considered indefinite-lived, they will not be amortized but will be tested for impairment on an annual basis and between annual tests if the Company becomes aware of any events occurring or changes in circumstances that would indicate a reduction in the fair value of the IPR&D assets below their respective carrying amounts. The following table represents the changes in IPR&D for the six months ended June 30, 2017: (in millions) Balance at December 31, 2016 $ Change in IPR&D — Balance at June 30, 2017 $ Goodwill and intangible assets are assessed annually for impairment on October 1 and whenever events or circumstances indicate that the carrying amount of an asset may not be recoverable. If it is determined that the full carrying amount of an asset is not recoverable, an impairment loss is recorded in the amount by which the carrying amount of the asset exceeds its fair value. |
Cash, Money Market Funds and Ma
Cash, Money Market Funds and Marketable Securities | 6 Months Ended |
Jun. 30, 2017 | |
Cash, Money Market Funds and Marketable Securities | |
Cash, Money Market Funds and Marketable Securities | Note 5. Cash, Money Market Funds and Marketable Securities As of June 30, 2017, the Company held $37.4 million in cash and cash equivalents and $189.8 million of available-for-sale securities which are reported at fair value on the Company’s Consolidated Balance Sheets. Unrealized holding gains and losses are reported within accumulated other comprehensive income/ (loss) in the statements of comprehensive loss. If a decline in the fair value of a marketable security below the Company’s cost basis is determined to be other than temporary, such marketable security is written down to its estimated fair value as a new cost basis and the amount of the write-down is included in earnings as an impairment charge. To date, only temporary impairment adjustments have been recorded. The Company regularly invests excess operating cash in deposits with major financial institutions, money market funds, notes issued by the U.S. government, as well as fixed income investments and U.S. bond funds both of which can be readily purchased and sold using established markets. The Company believes that the market risk arising from its holdings of these financial instruments is mitigated as many of these securities are either government backed or of the highest credit rating. Investments that have original maturities greater than 3 months but less than 1 year are classified as short-term, while investments that have maturities greater than 1 year are classified as long-term. For the six months ended June 30, 2017, the Company recognized a gain of $0.2 million, related to derivative instruments not designated as hedging instruments in other expense in the Consolidated Statements of Operations. Because the forward contract expired in June 2017, there was no liability in the Consolidated Balance Sheets as of June 30, 2017. Cash and available-for-sale securities are all current unless mentioned otherwise and consisted of the following as of June 30, 2017 and December 31, 2016 (in thousands): As of June 30, 2017 Cost Gross unrealized Gain Gross unrealized Loss Fair Value Cash balances $ $ — $ — $ Corporate debt securities, current portion ) Commercial paper — Money market — — Certificate of deposit — — $ $ $ ) $ Included in cash and cash equivalents $ $ — $ — $ Included in marketable securities ) Total cash and marketable securities $ $ ) $ As of December 31, 2016 Cost Unrealized Gain Unrealized Loss Fair Value Cash balances $ $ — $ — $ Corporate debt securities, current portion ) Commercial paper — Money market — — Certificate of deposit — — $ $ $ ) $ Included in cash and cash equivalents $ $ — $ — $ Included in marketable securities ) Total cash and marketable securities $ $ ) $ For the six months ended June 30, 2017 and the year ended December 31, 2016, there were no realized gains or losses. The cost of securities sold is based on the specific identification method. Unrealized loss positions in the available for sale securities as of June 30, 2017 and December 31, 2016 reflect temporary impairments that have been in a loss position for less than twelve months and as such are recognized in other comprehensive gain/ (loss). The fair value of these available for sale securities in unrealized loss positions was $93.7 million and $58.7 million as of June 30, 2017 and December 31, 2016, respectively. The Company holds available-for-sale investment securities which are reported at fair value on the Company’s balance sheet. Unrealized holding gains and losses are reported within accumulated other comprehensive income (“AOCI”) in the statements of comprehensive loss. |
Inventories
Inventories | 6 Months Ended |
Jun. 30, 2017 | |
Inventories | |
Inventories | Note 6. Inventories Inventories consist of work in process and finished goods related to the manufacture of Galafold™. The following table summarizes the components of inventories at June 30, 2017 (in thousands): June 30, 2017 December 31, 2016 Work-in-process $ $ Finished goods Total inventories $ $ Inventory manufactured prior to commercialization was expensed to research and development. Inventories are reviewed periodically to identify slow-moving or obsolete inventory based on projected sales activity, as well as product shelf-life. In evaluating the recoverability of inventories produced, the Company considers the probability that revenue will be obtained from the future sale of the related inventory. Inventory becomes obsolete when it has aged past its shelf-life, cannot be recertified and is no longer usable or able to be sold, or the inventory has been damaged. In such instances, a full reserve is taken against such inventory. Expired inventory is disposed of and the related costs are recognized as cost of product sales in the consolidated statement of operations. There have been no write-downs of inventory from the time inventory was first capitalized nor have any inventory reserves been recorded to date. |
Debt Instruments
Debt Instruments | 6 Months Ended |
Jun. 30, 2017 | |
Debt Instruments | |
Debt Instruments | Note 7. Debt Instruments 2016 Convertible Debt On December 21, 2016, the Company issued at par value $250 million aggregate principal amount of unsecured Convertible Senior Notes due 2023 (the “Convertible Notes”), which included the exercise in full of the $25 million over-allotment option granted to the initial purchasers of the Notes, in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act (the “Note Offering”). Interest is payable semiannually on June 15 and December 15 of each year, beginning on June 15, 2017. The Notes will mature on December 15, 2023, unless earlier repurchased, redeemed, or converted in accordance with their terms. The Notes are convertible at the option of the holders, under certain circumstances and during certain periods, into cash, shares of the Company’s Common Stock or a combination thereof and may be settled as described below. The net proceeds from the Note Offering were $243.1 million, after deducting fees and estimated expenses payable by the Company. In addition, the Company used approximately $13.5 million of the net proceeds from the issuance of the Convertible Notes to pay the cost of the capped call transactions (“Capped Call Confirmations”) that the Company entered into in connection with the issuance of the Convertible Notes. The Convertible Notes are governed by an indenture dated December 21, 2016 (the “Indenture”) by and between the Company and Wilmington Trust, National Association, as trustee. The Convertible Notes are initially convertible into approximately 40,849,675 shares of the Company’s Common Stock under certain circumstances prior to maturity at a conversion rate of 163.3987 shares per $1,000 principal amount of Convertible Notes, which represents a conversion price of approximately $6.12 per share of Common Stock, subject to adjustment under certain conditions. Holders may convert their Convertible Notes at their option at specified times prior to the maturity date of December 15, 2023, only if: · during any fiscal quarter commencing after March 31, 2017, the last reported sale price of the Company’s Common Stock for at least 20 trading days in the period of 30 consecutive trading days ending on the last trading day of the immediately preceding fiscal quarter is equal to or more than 130% of the conversion price of the Convertible Notes on the last day of such preceding fiscal quarter; · a Holder submits its Convertible Notes for conversion during the five business day period following any five consecutive trading day period in which the trading price for the Convertible Notes, per $1,000 principal amount of the Convertible Notes, for each such trading day was less than 98% of the product of the last reported sale price of the Company’s Common Stock and the conversion rate of the Convertible Notes on such date; · the Company issues to all or substantially all of the holders of Common Stock rights options or warrants entitling them for a period of not more than 60 calendar days after the date of such issuance to subscribe for or purchase shares of the Common Stock, at a price per share less than the average of the Last Reported Sale Prices of the Common Stock for the 10 consecutive Trading Day period ending on, and including, the Trading Day immediately preceding the date of announcement of such issuance or distributes to all or substantially all holders of the Common Stock the Company’s assets, debt securities or rights to purchase the Company’s securities which distribution has a per share value of exceeding 10% of the Last Reported Sale Price of the Common Stock on the Trading Day immediately preceding the date of announcement of such distribution · the Company enters into specified corporate transactions; or · the Company has had a call for redemption, the holder can convert up until the second trading day immediately preceding the redemption date The Convertible Notes will be convertible, at the option of the note holders, regardless of whether any of the foregoing conditions have been satisfied, on or after September 15, 2023 at any time prior to the close of business on the second scheduled trading day immediately preceding the stated maturity date of December 15, 2023. The last reported sale price of the Company’s Common Stock was equal to or more than 130% of the conversion price of the Convertible Notes for atleast 20 trading days of the 30 consecutive trading days ending on the last day of the second quarter. As a result, the Convertible Notes are currently convertible into the Company’s Common stock as discussed above and at least until the end of the third quarter. Upon the occurrence of a make-whole fundamental change or if the Company call all or any portion of the Convertible Notes for redemption prior to July 1, 2020, the Company will, in certain circumstances, increase the conversion rate by a number of additional shares for a holder that elects to convert its Convertible Notes in connection with such make-whole fundamental change or during the related redemption period. Upon conversion, the Company may pay cash, shares of the Company’s Common Stock or a combination of cash and stock, as determined by the Company in its discretion. The Company accounts for the Convertible Notes as a liability and equity component where the carrying value of the liability component will be valued based on a similar instrument. In accounting for the issuance of the Convertible Notes, the Company separated the Convertible Notes into liability and equity components. The equity component is not re-measured as long as it continues to meet the conditions for equity classification. In accounting for the issuance of the Convertible Notes, the Company separated the Convertible Notes into liability and equity components based on their relative values. The carrying amount of the liability component was calculated by measuring the fair value of a similar liability that does not have an associated convertible feature. The carrying amount of the equity component, representing the conversion option, was determined by deducting the fair value of the liability component from the par value of the Convertible Notes. The difference between the principal amount of the Convertible Notes and the liability component represents the debt discount, which is recorded as a direct deduction from the related debt liability in the Consolidated Balance Sheets and amortized to interest expense using the effective interest method over the seven-year term of the Convertible Notes. The equity component of the Convertible Notes of approximately $88.3 million is included in additional paid-in capital in the Consolidated Balance Sheets and is not remeasured as long as it continues to meet the conditions for equity classification. Additionally, the Company recorded a deferred tax liability of $29.8 million in relation to the Convertible Notes. The Company incurred transaction costs of approximately $7.5 million, including approximately $6.9 million that was paid from the gross proceeds of the Convertible Notes offering. In accounting for the transaction costs, the Company allocated the total amount incurred to the liability and equity components using the same proportions as the proceeds from the Convertible Notes. Transaction costs attributable to the liability component were recorded as a direct deduction from the related debt liability in the Consolidated Balance Sheets and amortized to interest expense over the seven-year term of the Convertible Notes. Transaction costs attributable to the equity component were netted with the equity component in additional-paid-in-capital. The Convertible Notes consist of the following (in thousands): as of June 30, 2017 and December 31, 2016: Liability component June 30, 2017 December 31, 2016 Principal $ $ Less: debt discount (1) ) ) Less: deferred financing(1) ) ) Net carrying value of the debt $ $ (1) The fair value of the debt at June 30, 2017 was approximately $445.9 million. The following table sets forth total interest expense recognized related to the Convertible Notes for the three and six months ended June 30, 2017: Components (In thousands) Three Months Six Months Contractual interest expense $ $ Amortization of deferred financing Amortization of debt discount Total $ $ Effective interest rate of the liability component was 10.85%. The Capped Call Confirmations of $13.5 million are expected generally to reduce the potential dilution to the Common Stock upon any conversion of the Convertible Notes and/or offset the cash payments the Company is required to make in excess of the principal amount upon conversion of the Notes in the event that the market price of the Common Stock is greater than the strike price of the Capped Call Confirmations (which initially corresponds to the initial conversion price of the Convertible Notes and is subject to certain adjustments under the terms of the Capped Call Confirmations), with such reduction and/or offset subject to a cap based on the cap price of the Capped Call Confirmations. The Capped Call Confirmations have an initial cap price of $7.20 per share, which represents a premium of approximately 50% over the closing price of the Company’s Common Stock on the NASDAQ Global Market on December 15, 2016, and is subject to certain adjustments under the terms of the Capped Call Confirmations. The Capped Call Confirmations will cover, subject to anti-dilution adjustments substantially similar to those applicable to the Convertible Notes, the number of shares of Common Stock that will underlie the Convertible Notes. The Capped Call Confirmations do not meet the criteria for separate accounting as a derivative as they are indexed to the Company’s Common Stock. The premiums paid for the Capped Call Confirmations have been included as a net reduction to additional paid-in capital. |
Stockholders' Equity
Stockholders' Equity | 6 Months Ended |
Jun. 30, 2017 | |
Stockholders' Equity | |
Stockholders' Equity | Note 8. Stockholders’ Equity Common Stock and Warrants As of June 30, 2017, the Company was authorized to issue 250 million shares of Common Stock. Dividends on Common Stock will be paid when, and if, declared by the board of directors. Each stockholder is entitled to vote on all matters that are appropriate for stockholder voting and is entitled to one vote for each share held. As discussed in “—Note 7. Debt Instruments”, on December 21, 2016, the Company issued $250 million aggregate principal amount of Convertible Notes in a private offering. The Notes will mature on December 15, 2023, unless earlier repurchased, redeemed, or converted in accordance with their terms. The Notes are convertible at the option of the holders, under certain circumstances and during certain periods, into cash, shares of the Company’s Common Stock or a combination thereof. Prior to the close of business on the business day immediately preceding September 15, 2023, the Notes are convertible at the option of the holders of the Notes only under certain conditions. On or after September 15, 2023, until the close of business on the second business day immediately preceding the maturity date, holders of the Notes may convert their Notes at their option at the conversion rate then in effect, irrespective of these conditions. The Company will settle conversions of the Notes by paying or delivering, as the case may be, cash, shares of Common Stock, or a combination of cash and shares of Common Stock, at the Company’s election. The conversion rate will initially be 163.3987 shares of Common Stock per $1,000 principal amount of Notes (equivalent to an initial conversion price of approximately $6.12 per share of Common Stock). The conversion rate is subject to customary adjustments upon the occurrence of certain events. Equity Incentive Plan The Company’s Equity Incentive Plans consist of the Amended and Restated 2007 Equity Incentive Plan (the “Plan”) and the 2007 Director Option Plan (the “2007 Director Plan”). The Plan provides for the granting of restricted stock and options to purchase common stock in the Company to employees, advisors and consultants at a price to be determined by the Company’s board of directors. The Plan is intended to encourage ownership of stock by employees and consultants of the Company and to provide additional incentives for them to promote the success of the Company’s business. The 2007 Director Plan is intended to promote the recruiting and retention of highly qualified eligible directors and strengthen the commonality of interest between directors and stockholders by encouraging ownership of common stock of the Company. The Board of Directors, or its committee, is responsible for determining the individuals to be granted options, the number of options each individual will receive, the option price per share, and the exercise period of each option. Stock Option Grants The fair value of the stock options granted is estimated on the date of grant using a Black-Scholes option pricing model with the following weighted-average assumptions: Three Months Six Months Ended 2017 2016 2017 2016 Expected stock price volatility % % % % Risk free interest rate % % % % Expected life of options (years) Expected annual dividend per share $ $ $ $ A summary of the Company’s stock options for the six months ended June 30, 2017 is as follows: Number of Weighted Weighted Aggregate (in thousands) (in millions) Options outstanding, December 31, 2016 $ Granted $ Exercised ) $ Forfeited ) $ Options outstanding, June 30, 2017 $ 7.4 years $ Vested and unvested expected to vest, June 30, 2017 $ 7.3 years $ 57.2 Exercisable at June 30, 2017 $ 6.2 years $ 34.2 As of June 30, 2017, the total unrecognized compensation cost related to non-vested stock options granted was $34.7 million and is expected to be recognized over a weighted average period of 2.6 years. Restricted Stock Units (“RSUs”) and Performance-Based Restricted Stock Units RSUs awarded under the Plan are generally subject to graded vesting and are contingent on an employee’s continued service. RSUs are generally subject to forfeiture if employment terminates prior to the release of vesting restrictions. The Company expenses the cost of the RSUs, which is determined to be the fair market value of the shares of Common Stock underlying the RSUs at the date of grant, ratably over the period during which the vesting restrictions lapse. A summary of non-vested RSU activity under the Plan for the six months ended June 30, 2017 is as follows: Number of Share Weighted Weighted Average Aggregate Intrinsic (in thousands) (in millions) Non-vested units as of December 31, 2016 $ Granted $ Vested ) $ Forfeited ) $ Non-vested units as of June 30, 2017 $ 2.9 years $ On December 30, 2016, the Compensation Committee approved a form of Performance-Based Restricted Stock Unit Award Agreement (the “Performance-Based RSU Agreement”), to be used for performance-based RSUs granted to participants under the Amended and Restated Amicus Therapeutics, Inc. 2007 Equity Incentive Plan, including named executive officers. Certain awards under the form of Performance-Based RSU Agreement were granted in January 2017. The table above includes 401,413 market performance-based restricted stock units (“MPRSUs”) granted to executives. Vesting of these awards is contingent upon the Company meeting certain total shareholder return (“TSR”) levels as compared to a select peer group over the next three years. The MPRSUs cliff vest at the end of the three-year period and have a maximum potential to vest at 200% (802,826 shares) based on TSR performance. The related share-based compensation expense is determined based on the estimated fair value of the underlying shares on the date of grant and is recognized straight-line over the vesting term. The estimated fair value per share of the MPRSUs was $8.08 and was calculated using a Monte Carlo simulation model. The table above also includes 401,413 performance based awards that will vest over the next three years based on the Company achieving certain clinical milestones. For the six months ended June 30, 2017, 203,106 of the RSUs vested and all non-vested units are expected to vest over their normal term. As of June 30, 2017, there was $12.4 million of total unrecognized compensation cost related to unvested RSUs with service-based vesting conditions. These costs are expected to be recognized over a weighted average period of 3 years. Compensation Expense Related to Equity Awards The following table summarizes information related to compensation expense recognized in the statements of operations related to the equity awards (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2017 2016 2017 2016 Equity compensation expense recognized in: Research and development expense $ $ $ Selling, general and administrative expense Total equity compensation expense $ $ $ |
Assets and Liabilities Measured
Assets and Liabilities Measured at Fair Value | 6 Months Ended |
Jun. 30, 2017 | |
Assets and Liabilities Measured at Fair Value | |
Assets and Liabilities Measured at Fair Value | Note 9. Assets and Liabilities Measured at Fair Value The Company’s financial assets and liabilities are measured at fair value and classified within the fair value hierarchy, which is defined as follows: Level 1 — Quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date. Level 2 — Inputs other than quoted prices in active markets that are observable for the asset or liability, either directly or indirectly. Level 3 — Inputs that are unobservable for the asset or liability. A summary of the fair value of the Company’s recurring assets and liabilities aggregated by the level in the fair value hierarchy within which those measurements fall as of June 30, 2017 are identified in the following table (in thousands): Level 2 Total Assets: Commercial paper $ $ Corporate debt securities Money market funds $ $ Level 2 Level 3 Total Liabilities: Contingent consideration payable $ — $ $ Derivative liability — — — Deferred compensation plan liability — $ $ $ A summary of the fair value of the Company’s recurring assets and liabilities aggregated by the level in the fair value hierarchy within which those measurements fall as of December 31, 2016 are identified in the following table (in thousands): Level 2 Total Assets: Commercial paper $ $ Corporate debt securities Money market funds $ $ Level 2 Level 3 Total Liabilities: Contingent consideration payable $ — $ $ Derivative liability — Deferred compensation plan liability — $ $ $ See “—Note 7. Debt Instruments” for the carrying amount and estimated fair value of the Company’s Convertible Notes due in 2023, that falls into Level 2 category within the fair value level hierarchy. The fair value was determined using broker quotes in a non-active market for valuation. The Company did not have any Level 3 assets as of June 30, 2017 or as of December 31, 2016. Cash, Money Market Funds and Marketable Securities The Company classifies its cash within the fair value hierarchy as Level 1 as these assets are valued using quoted prices in active market for identical assets at the measurement date. The Company considers its investments in marketable securities as available for sale and classifies these assets and the money market funds within the fair value hierarchy as Level 2 primarily utilizing broker quotes in a non-active market for valuation of these securities. No changes in valuation techniques or inputs occurred during the six months ended June 30, 2017. No transfers of assets between Level 1 and Level 2 of the fair value measurement hierarchy occurred during the six months ended June 30, 2017. Contingent Consideration Payable The contingent consideration payable resulted from the acquisitions of Scioderm and Callidus Biopharma, Inc. (“Callidus”). The most recent valuation was determined using a probability weighted discounted cash flow valuation approach. Using this approach, expected future cash flows are calculated over the expected life of the agreement, are discounted, and then exercise scenario probabilities are applied. The valuation is performed quarterly. Gains and losses are included in the statement of operations. As discussed in “—Note 3. Acquisitions,” on July 5, 2016, the Company entered into the MiaMed Agreement with MiaMed. MiaMed is a pre-clinical biotechnology company focused on developing protein replacement for CDKL5 and related diseases. Under the terms of the MiaMed Agreement, the Company agreed to pay up to an additional $83.0 million in connection with the achievement of certain clinical, regulatory and commercial milestones, for a potential aggregate deal value of $89.5 million. The MiaMed Agreement was accounted for as an asset acquisition and as such the Company determined that a liability for future milestone payments is not required to be recorded until the actual contingencies are met and will be recorded to research and development expenses when the contingency is resolved. The contingent consideration payable for Scioderm and Callidus has been classified as a Level 3 recurring liability as its valuation requires substantial judgment and estimation of factors that are not currently observable in the market. If different assumptions were used for the various inputs to the valuation approach the estimated fair value could be significantly higher or lower than the fair value the Company determined. The Company may be required to record losses in future periods, including expenses related to CDKL5. The following significant unobservable inputs were used in the valuation of the contingent consideration payable to former Scioderm stockholders: Contingent Consideration Fair value as of Valuation Technique Unobservable Input Range Clinical and regulatory milestones $228.1 million Probability weighted discounted cash flow Discount rate 1.0%-1.3% Probability of achievement of milestones 66.5% -70.0% Projected year of payments 2017-2019 Revenue-based milestones $26.6 million Monte Carlo Revenue volatility 51% Probability of achievement of milestones 66.5% Discount rate 1.5%-2.4% Projected year of payments 2019-2035 The following significant unobservable inputs were used in the valuation of the contingent consideration payable of Callidus for the ATB200 Pompe program: Contingent Consideration Fair value as of Valuation Technique Unobservable Input Range Clinical and regulatory milestones $10.3 million Probability weighted discounted cash flow Discount rate 12.5% Probability of achievement of milestones 32.0%-45.0% Projected year of payments 2018-2022 Contingent consideration liabilities are remeasured to fair value each reporting period using projected revenues, discount rates, probabilities of payment and projected payment dates. Projected contingent payment amounts related to clinical and regulatory based milestones are discounted back to the current period using a discounted cash flow model. Revenue-based payments are valued using a monte-carlo valuation model, which simulates future revenues during the earn-out period using management’s best estimates. Projected revenues are based on the Company’s most recent internal operational budgets and long-range strategic plans. Increases in projected revenues and probabilities of payment may result in higher fair value measurements. Increases in discount rates and the time to payment may result in lower fair value measurements. Increases or decreases in any of those inputs together, or in isolation, may result in a significantly lower or higher fair value measurement. There is no assurance that any of the conditions for the milestone payments will be met. The following table shows the change in the balance of contingent consideration payable for the three and six months ended June 30, 2017 and 2016, respectively (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2017 2016 2017 2016 Balance, beginning of the period $ $ Payment of contingent consideration in cash ) ) ) ) Payment of contingent consideration in stock — ) — ) Unrealized change in fair value change during the period, included in Statement of Operations Balance, end of the period $ $ $ Deferred Compensation Plan- Investment and Liability The Deferral Plan provides certain key employees and members of the Board of Directors with an opportunity to defer the receipt of such participant’s base salary, bonus and director’s fees, as applicable. Deferral Plan assets are classified as trading securities and recorded at fair value with changes in the investments’ fair value recognized in the period they occur. The asset investments consist of market exchanged mutual funds. The Company considers its investments in marketable securities, as available-for-sale and classifies these assets and related liability within the fair value hierarchy as Level 2 primarily utilizing broker quotes in a non-active market for valuation of these securities. Foreign Currency Exchange Rate Exposure In June 2016, the Company entered into a forward contract to economically hedge transactional exposure associated with commitments arising from trade accounts payable denominated in a currency other than the functional currency of the respective operating entity. The Company did not designate this forward contract as a hedging instrument and carried the liability of $0.3 million as other current liability in the Consolidated Balance Sheet as of December 31, 2016. The forward contract settled in June 2017. Accordingly, there is no liability as of June 30, 2017. |
Basic and Diluted Net Loss per
Basic and Diluted Net Loss per Common Share | 6 Months Ended |
Jun. 30, 2017 | |
Basic and Diluted Net Loss per Common Share | |
Basic and Diluted Net Loss per Common Share | Note 10. Basic and Diluted Net Loss per Common Share The following table provides a reconciliation of the numerator and denominator used in computing basic and diluted net loss attributable to common stockholders per common share (in thousands except share amounts): (In thousands, except per share Three Months Ended June 30, Six Months Ended June 30, amounts) 2017 2016 2017 2016 Numerator: Net loss attributable to common stockholders $ ) $ ) $ ) $ ) Denominator: Weighted average common shares outstanding — basic and diluted Dilutive Common Stock equivalents would include the dilutive effect of Common Stock options, convertible debt units, RSUs and warrants for Common Stock equivalents. Potentially dilutive Common Stock equivalents were excluded from the diluted earnings per share denominator for all periods because of their anti-dilutive effect. The table below presents potential shares of Common Stock that were excluded from the computation as they were anti-dilutive using the treasury stock method (in thousands): As of June 30, 2017 2016 Options to purchase common stock Convertible debt — Outstanding warrants, convertible to common stock Unvested restricted stock units Vested restricted stock units, unissued — Total number of potentially issuable shares |
Commitments and Contingencies
Commitments and Contingencies | 6 Months Ended |
Jun. 30, 2017 | |
Commitments and Contingencies | |
Commitments and Contingencies | Note 11. Commitments and Contingencies Since October 1, 2015, three purported securities class action lawsuits have been commenced in the United States District Court for New Jersey, naming as defendants the Company, its Chairman and Chief Executive Officer, and in one of the actions, its Chief Medical Officer. The lawsuits allege violations of the Securities Exchange Act of 1934 in connection with allegedly false and misleading statements made by the Company related to the regulatory approval path for migalastat. The plaintiffs seek, among other things, damages for purchasers of the Company’s Common Stock during different periods, all of which fall between March 19, 2015 and October 1, 2015. It is possible that additional suits will be filed, or allegations received from stockholders, with respect to similar matters and also naming the Company and/or its officers and directors as defendants. On May 26, 2016, the Court consolidated these lawsuits into a single action and appointed a lead plaintiff. The lead plaintiff filed a Consolidated Amended Class Action Complaint on July 11, 2016. On August 25, 2016, the defendants filed a motion to dismiss in response to the Consolidated Amended Class Action Complaint. This motion to dismiss was fully briefed on October 28, 2016, but has not been decided. Lead plaintiff and defendants have reached an agreement in principal to fully and finally settle all claims asserted in the Consolidated Amended Class Action Complaint. On June 29, 2017, the Court granted preliminary approval to the settlement. In connection with the Court’s preliminary approval, the settlement amount was paid into the plaintiff’s fund. The settlement is immaterial to the Company’s consolidated financial statements and is subject to final court approval. A fairness hearing to determine whether the settlement will be approved is scheduled for November 2, 2017. The settlement amount was covered under insurance. On or about March 3, 2016, a derivative lawsuit was filed by an Amicus shareholder purportedly on Amicus’ behalf in the Superior Court of New Jersey, Middlesex County, Chancery Division, against various officers and directors of the Company. Amicus itself is named as a nominal defendant. The derivative lawsuit alleges similar facts and circumstances as the three purported securities class action lawsuits described above and further alleges claims for breach of state law fiduciary duties, waste of corporate assets, unjust enrichment, abuse of control, and gross mismanagement based on allegedly false and misleading statements made by Amicus related to the regulatory approval path for migalastat HCl. The plaintiff seeks, among other things, to require the Amicus Board to take certain actions to reform its corporate governance procedures, including greater shareholder input and a provision to permit shareholders to nominate candidates for election to the Board, along with restitution, costs of suit and attorney’s fees. On February 7, 2017, the complaint was dismissed by the Court without prejudice. These lawsuits and any other related lawsuits are subject to inherent uncertainties and the actual cost will depend upon many unknown factors. The outcome of the litigation is necessarily uncertain and we could be forced to expend significant resources in the defense of these suits, and we may not prevail. |
Subsequent Events
Subsequent Events | 6 Months Ended |
Jun. 30, 2017 | |
Subsequent Events | |
Subsequent Events | Note 12. Subsequent Events On July 12, 2017, the Company entered into the Underwriting Agreement with J.P. Morgan Securities LLC and Goldman Sachs & Co. LLC, as representatives of the several underwriters set forth on Schedule 1 thereto, relating to the Offering. Under the terms of the Underwriting Agreement, the Company issued and sold 21,122,449 shares at a price to the public of $12.25 per share, resulting in gross proceeds of $258.8 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by the Company. The Offering closed on July 18, 2017 and the Company received net proceeds from the Offering, after deducting underwriting discounts and commissions and offering expenses payable by the Company of $243.2 million. The Offering was made pursuant to the Company’s registration statement on Form S-3 (Registration No. 333-211005) filed with the U.S. Securities and Exchange Commission (the “ Commission “) on April 29, 2016, which became effective automatically upon the filing thereof. A preliminary prospectus supplement relating to the Offering was filed with the Commission on July 12, 2017, and a final prospectus supplement relating to the Offering was filed with the Commission on July 13, 2017. The Company expects to use the net proceeds of the Offering for investment in the U.S. and international commercial infrastructure for migalastat HCl, investment in manufacturing capabilities for ATB200, the continued clinical development of its product candidates, research and development expenditures, clinical and pre-clinical trial expenditures, commercialization expenditures and for other general corporate purposes, which may include working capital, capital expenditures, the funding of in-licensing agreements for product candidates, additional technologies or other forms of intellectual property, the acquisition of assets or businesses that are complementary to the Company’s existing business and general and administrative expenses. |
Summary of Significant Accoun19
Summary of Significant Accounting Policies (Policies) | 6 Months Ended |
Jun. 30, 2017 | |
Summary of Significant Accounting Policies | |
Basis of Presentation | Basis of Presentation The Company has prepared the accompanying unaudited consolidated financial statements in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10-01 of Regulation S-X. Accordingly, they do not include all of the information and disclosures required by U.S. GAAP for complete financial statements. In the opinion of management, the accompanying unaudited financial statements reflect all adjustments, which include only normal recurring adjustments, necessary to present fairly the Company’s interim financial information. The accompanying unaudited consolidated financial statements and related notes should be read in conjunction with the Company’s financial statements and related notes as contained in the Company’s Annual Report on Form 10-K, as amended, for the year ended December 31, 2016. For a complete description of the Company’s accounting policies, please refer to the Annual Report on Form 10-K, as amended for the year ended December 31, 2016. |
Consolidation | Consolidation The consolidated financial statements include the accounts of the Company and its subsidiaries. Intercompany accounts and transactions have been eliminated in consolidation. |
Foreign Currency Transactions | Foreign Currency Transactions The functional currency for most of the Company’s foreign subsidiaries is their local currency. For non-U.S. subsidiaries that transact in a functional currency other than the U.S. dollar, assets and liabilities are translated at current rates of exchange at the balance sheet date. Income and expense items are translated at the average foreign exchange rates for the period. Adjustments resulting from the translation of the financial statements of the Company’s foreign operations into U.S. dollars are excluded from the determination of net income and are recorded in accumulated other comprehensive income, a separate component of stockholders’ equity. The Company transacts business in various foreign countries and therefore, is subject to risk of foreign currency exchange rate fluctuations. As such, in June 2016, the Company entered into a forward contract to economically hedge transactional exposure associated with commitments arising from trade accounts payable denominated in a currency other than the functional currency of the respective operating entity. The Company does not designate this forward contract as a hedging instrument under applicable accounting guidance and, therefore, changes in fair value are recorded as other expense in the Consolidated Statements of Operations. The forward contract expired in June 2017. |
Use of Estimates | Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates. |
Concentration of Credit Risk | Concentration of Credit Risk The Company’s financial instruments that are exposed to concentration of credit risk consist primarily of cash and cash equivalents and marketable securities. The Company maintains its cash and cash equivalents in bank accounts, which, at times, exceed federally insured limits. The Company invests its marketable securities in high-quality commercial financial instruments. The Company has not recognized any losses from credit risks on such accounts during any of the periods presented. The Company believes it is not exposed to significant credit risk on cash and cash equivalents or its marketable securities. The Company is subject to credit risk from its accounts receivable related to its product sales of Galafold™. The majority of the Company’s accounts receivable at June 30, 2017 have arisen from product sales in Germany. The Company will periodically assess the financial strength of its customers to establish allowances for anticipated losses, if any. For accounts receivable that have arisen from named patient sales, the payment terms are predetermined and the Company evaluates the creditworthiness of each customer on a regular basis. To date, the Company has not incurred any credit losses. |
Revenue Recognition | Revenue Recognition The Company recognizes revenue when amounts are realized or realizable and earned. Revenue is considered realizable and earned when persuasive evidence of an arrangement exists, title to product and associated risk of loss has passed to the customer, which is typically upon receipt by the end customer, the price is fixed or determinable, collection of the amounts due are reasonably assured and the Company has no further performance obligations. The Company’s net product sales consist solely of sales of Galafold™ for the treatment of Fabry disease in the EU. The Company has recorded revenue on sales where Galafold™ is available either on a commercial basis or through a reimbursed early access program. Orders for Galafold™ are generally received from pharmacies and the ultimate payor is typically a government authority. The Company records revenue net of estimated third party discounts and rebates. Allowances are recorded as a reduction of revenue at the time revenues from product sales are recognized. These allowances are adjusted to reflect known changes in factors and may impact such allowances in the quarter those changes are known. Allowance as of June 30, 2017 are immaterial. |
Inventories and Cost of Goods Sold | Inventories and Cost of Goods Sold Prior to regulatory approval of Galafold™, the Company expensed all manufacturing costs related to Galafold™ as research and development expense. Upon regulatory approval, the Company began capitalizing costs related to the purchase and manufacture of Galafold™. Inventories are stated at the lower of cost and net realizable value, determined by the first-in, first-out method. Inventories are reviewed periodically to identify slow-moving or obsolete inventory based on projected sales activity as well as product shelf-life. In evaluating the recoverability of inventories produced, the probability that revenue will be obtained from the future sale of the related inventory is considered and inventory value is written down for inventory quantities in excess of expected requirements. Expired inventory is disposed of and the related costs are recognized as cost of product sales in the consolidated statements of operations. Cost of goods sold includes the cost of inventory sold, manufacturing and supply chain costs, product shipping and handling costs, provisions for excess and obsolete inventory, as well as royalties payable. A portion of the inventory available for sale was expensed as research and development costs prior to regulatory approval and as such the cost of goods sold and related gross margins are not necessarily indicative of future cost of goods sold and gross margin. |
Fair Value Measurements | Fair Value Measurements The Company records certain asset and liability balances under the fair value measurements as defined by the FASB guidance. Current FASB fair value guidance emphasizes that fair value is a market-based measurement, not an entity-specific measurement. Therefore, a fair value measurement should be determined based on the assumptions that market participants would use in pricing the asset or liability. As a basis for considering market participant assumptions in fair value measurements, current FASB guidance establishes a fair value hierarchy that distinguishes between market participant assumptions based on market data obtained from sources independent of the reporting entity (observable inputs that are classified within Levels 1 and 2 of the hierarchy) and the reporting entity’s own assumptions that market participants assumptions would use in pricing assets or liabilities (unobservable inputs classified within Level 3 of the hierarchy). Level 1 inputs utilize quoted prices (unadjusted) in active markets for identical assets or liabilities that the Company has the ability to access at measurement date. Level 2 inputs are inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly. Level 2 inputs may include quoted prices for similar assets and liabilities in active markets, as well as inputs that are observable for the asset or liability (other than quoted prices), such as interest rates, foreign exchange rates, and yield curves that are observable at commonly quoted intervals. Level 3 inputs are unobservable inputs for the asset or liability, which is typically based on an entity’s own assumptions, as there is little, if any, related market activity. In instances where the determination of the fair value measurement is based on inputs from different levels of the fair value hierarchy, the level in the fair value hierarchy within which the entire fair value measurement falls is based on the lowest level input that is significant to the fair value measurement in its entirety. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment, and considers factors specific to the asset or liability. |
Contingent Liabilities | Contingent Liabilities On an ongoing basis, the Company may be involved in various claims, and legal proceedings. On a quarterly basis, the Company reviews the status of each significant matter and assesses its potential financial exposure. If the potential loss from any claim, asserted or unasserted, or legal proceeding is considered probable and the amount can be reasonably estimated, the Company will accrue a liability for the estimated loss. Because of uncertainties related to claims and litigation, accruals will be based on the Company’s best estimates based on available information. On a periodic basis, as additional information becomes available, or based on specific events such as the outcome of litigation or settlement of claims, the Company may reassess the potential liability related to these matters and may revise these estimates, which could result in material adverse adjustments to the Company’s operating results. |
Recent Accounting Pronouncements | Recent Accounting Pronouncements In July 2017, the FASB issued ASU 2017-11, Earnings Per Share (Topic 260); Distinguishing Liabilities from Equity (Topic 480); Derivatives and Hedging (Topic 815): (Part I) Accounting for Certain Financial Instruments with Down Round Features, (Part II) Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception . Part I of this Update addresses the complexity of accounting for certain financial instruments with down round features. Down round features are features of certain equity-linked instruments (or embedded features) that result in the strike price being reduced on the basis of the pricing of future equity offerings. When determining whether certain financial instruments should be classified as liabilities or equity instruments, a down round feature no longer precludes equity classification when assessing whether the instrument is indexed to an entity’s own stock. Part II of this Update addresses the difficulty of navigating Topic 480, Distinguishing Liabilities from Equity, because of the existence of extensive pending content in the FASB Accounting Standards Codification®. For public business entities, the amendments in Part I of this Update are effective for fiscal years, and years, beginning after December 15, 2018. Early adoption is permitted for all entities, including adoption in an interim period. The Company is currently assessing the impact that this standard will have on its consolidated financial statements. In May 2017, the FASB issued ASU 2017-09, Compensation—Stock Compensation (Topic 718): Scope of Modification Accounting . The amendments provide guidance on determining which changes to the terms and conditions of share-based payment awards require an entity to apply modification accounting under Topic 718 Compensation—Stock Compensation. An entity should account for the effects of a modification unless all the following are met: 1. The fair value (or calculated value or intrinsic value, if such an alternative measurement method is used) of the modified award is the same as the fair value (or calculated value or intrinsic value, if such an alternative measurement method is used) of the original award immediately before the original award is modified. If the modification does not affect any of the inputs to the valuation technique that the entity uses to value the award, the entity is not required to estimate the value immediately before and after the modification. 2. The vesting conditions of the modified award are the same as the vesting conditions of the original award immediately before the original award is modified. 3. The classification of the modified award as an equity instrument or a liability instrument is the same as the classification of the original award immediately before the original award is modified. The ASU is effective for all entities for annual periods, including interim periods within those annual periods, beginning after December 15, 2017. Early adoption is permitted, including adoption in any interim period. The Company is currently assessing the impact that this standard will have on its consolidated financial statements. In March 2017, the FASB issued ASU 2017-08, Receivables—Nonrefundable Fees and Other Costs (Subtopic 310-20), Premium Amortization on Purchased Callable Debt Securities. The amendments shorten the amortization period for certain callable debt securities held at a premium. Specifically, the amendments require the premium to be amortized to the earliest call date. The amendments do not require an accounting change for securities held at a discount; the discount continues to be amortized to maturity. The ASU is effective for public business entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. For other entities, the amendments are effective for fiscal years beginning after December 15, 2019, and interim periods within fiscal years beginning after December 15, 2020. Early adoption is permitted, including adoption in an interim period. If an entity early adopts in an interim period, any adjustments should be reflected as of the beginning of the fiscal year that includes that interim period. The amendments should be applied on a modified retrospective basis, with a cumulative-effect adjustment directly to retained earnings as of the beginning of the period of adoption. The Company is currently assessing the impact that this standard will have on its consolidated financial statements. In January 2017, the FASB issued ASU 2017-04, Intangibles - Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment . To simplify the subsequent measurement of goodwill, ASU 2017-04 eliminates Step 2 from the goodwill impairment test. The annual, or interim, goodwill impairment test is performed by comparing the fair value of a reporting unit with its carrying amount. An impairment charge should be recognized for the amount by which the carrying amount exceeds the reporting unit’s fair value; however, the loss recognized should not exceed the total amount of goodwill allocated to that reporting unit. In addition, income tax effects from any tax deductible goodwill on the carrying amount of the reporting unit should be considered when measuring the goodwill impairment loss, if applicable. ASU 2017-04 also eliminates the requirements for any reporting unit with a zero or negative carrying amount to perform a qualitative assessment and, if it fails that qualitative test, to perform Step 2 of the goodwill impairment test. An entity still has the option to perform the qualitative assessment for a reporting unit to determine if the quantitative impairment test is necessary. ASU 2017-04 should be applied on a prospective basis. The nature of and reason for the change in accounting principle should be disclosed upon transition. A public business entity that is a U.S. SEC filer should adopt ASU 2017-04 for its annual or any interim goodwill impairment tests in fiscal years beginning after December 15, 2019. Early adoption is permitted for interim or annual goodwill impairment tests performed on testing dates after January 1, 2017. The Company is currently assessing the impact that this standard will have on its consolidated financial statements. In January 2017, the FASB issued ASU 2017-01, Business Combinations (Topic 805): Clarifying the Definition of a Business. This Accounting Standards Update clarifies the definition of a business. The amendments affect all companies and other reporting organizations that must determine whether they have acquired or sold a business. The amendments in this update are effective for public companies for annual periods beginning after December 15, 2017, including interim periods within those periods. Early adoption is permitted under certain circumstances. The amendments should be applied prospectively as of the beginning of the period of adoption. The Company is currently assessing the impact that this standard will have on its consolidated financial statements. In October 2016, the FASB issued ASU 2016-16, Income Taxes (Topic 740): Intra-Entity Transfers of Assets Other Than Inventory . This Accounting Standards Update requires an entity to recognize the income tax consequences of an intra-entity transfer of an asset other than inventory when the transfer occurs. The amendments eliminate the exception for an intra-entity transfer of an asset other than inventory. The amendments in this Update are effective for public business entities for annual periods beginning after December 15, 2017, including interim reporting periods within those annual reporting periods. Early adoption is permitted for all entities in the first interim period if an entity issues interim financial statements. The Company is currently assessing the impact that this standard will have on its consolidated financial statements. The Company has not completed review of the impact of this guidance and does not expect this new guidance to have a material impact on its consolidated financial statements. In March 2016, the FASB issued ASU 2016-09, Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting . The amendments are intended to improve the accounting for employee share-based payments and affect all organizations that issue share-based payment awards to their employees. Several aspects of the accounting for share-based payment award transactions are simplified, including: (a) income tax consequences; (b) classification of awards as either equity or liabilities; and (c) classification on the statement of cash flows. For public companies, the amendments are effective for annual periods beginning after December 15, 2016, and interim periods within those annual periods. The Company adopted ASU 2016-09 on January 1, 2017. Due to the Company’s history of operating losses, the adoption did not result in changes to the Company’s Net loss or Retained earnings and the classification of excess tax benefits on the statement of cash flows for prior periods have not been adjusted. In connection with the adoption of ASU 2016-9, the Company made a policy election to continue its methodology for the development and application of its forfeiture rate. In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842) . This update requires the recognition of lease assets and lease liabilities on the balance sheet for all lease obligations and disclosing key information about leasing arrangements. This update requires the recognition of lease assets and lease liabilities by lessees for those leases classified as operating leases under previous generally accepted accounting principles. This update will be effective for the Company for all annual and interim periods beginning after December 15, 2018, including interim periods within those fiscal years. Early application is permitted for all public business entities and all nonpublic business entities upon issuance. The Company is currently assessing the impact that this standard will have on its consolidated financial statements. In May 2014, FASB issued ASU 2014-09, Revenue from Contracts with Customers which along with amendments issued in 2015 and 2016, will replace substantially all current US GAAP guidance on this topic and eliminate industry-specific guidance. ASU 2014-09 also requires additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to obtain or fulfill a contract. The guidance permits two methods of adoption: full retrospective method (retrospective application to each prior reporting period presented) or modified retrospective method (retrospective application with the cumulative effect of initially applying the guidance recognized at the date of initial application and providing certain additional disclosures). ASU 2014-09 will become effective for the Company during the first quarter of 2018. The Company continues to assess the impact of ASU 2014-09 on its business and financial statements and expects the adoption of ASU 2014-09 to have an impact to its financial reporting disclosures and internal controls over financial reporting (“ICFR”). The Company has developed implementation controls that allow the Company to properly and timely adopt the new revenue accounting standard on its effective date. The Company will make continuous updates to the quarterly and year-end disclosures, with a focus on both status and internal controls over financial reporting. The Company’s implementation plan includes a phased implementation project plan, an understanding of the new standard and its requirements, assessment of the Company’s revenue streams and specific contracts in the streams. Additionally, the Company continues to monitor modifications, clarifications and interpretations issued by the FASB that may impact its assessment. Upon completion of the Company’s implementation plan and evaluation of the remaining revenue contracts, the Company plans to adopt additional internal controls over financial reporting for any new revenue arrangements. The Company is on target to complete its assessment of ASU 2014-09 and the impact on the Company’s consolidated financial statements and related disclosures as of January 1, 2018. The Company has elected to adopt the new standard using the modified retrospective approach. |
Goodwill and IPR&D (Tables)
Goodwill and IPR&D (Tables) | 6 Months Ended |
Jun. 30, 2017 | |
Goodwill and IPR&D | |
Schedule of changes in goodwill | (in millions) Balance at December 31, 2016 $ Change in goodwill — Balance at June 30, 2017 $ |
Schedule of changes in IPR&D | (in millions) Balance at December 31, 2016 $ Change in IPR&D — Balance at June 30, 2017 $ |
Cash, Money Market Funds and 21
Cash, Money Market Funds and Marketable Securities (Tables) | 6 Months Ended |
Jun. 30, 2017 | |
Cash, Money Market Funds and Marketable Securities | |
Schedule of cash and available-for-sale securities | Cash and available-for-sale securities are all current unless mentioned otherwise and consisted of the following as of June 30, 2017 and December 31, 2016 (in thousands): As of June 30, 2017 Cost Gross unrealized Gain Gross unrealized Loss Fair Value Cash balances $ $ — $ — $ Corporate debt securities, current portion ) Commercial paper — Money market — — Certificate of deposit — — $ $ $ ) $ Included in cash and cash equivalents $ $ — $ — $ Included in marketable securities ) Total cash and marketable securities $ $ ) $ As of December 31, 2016 Cost Unrealized Gain Unrealized Loss Fair Value Cash balances $ $ — $ — $ Corporate debt securities, current portion ) Commercial paper — Money market — — Certificate of deposit — — $ $ $ ) $ Included in cash and cash equivalents $ $ — $ — $ Included in marketable securities ) Total cash and marketable securities $ $ ) $ |
Inventories (Tables)
Inventories (Tables) | 6 Months Ended |
Jun. 30, 2017 | |
Inventories | |
Schedule of inventories for the period | The following table summarizes the components of inventories at June 30, 2017 (in thousands): June 30, 2017 December 31, 2016 Work-in-process $ $ Finished goods Total inventories $ $ |
Debt Instruments (Tables)
Debt Instruments (Tables) | 6 Months Ended |
Jun. 30, 2017 | |
Debt Instruments | |
Schedule of liability components of the Convertible Notes | The Convertible Notes consist of the following (in thousands): as of June 30, 2017 and December 31, 2016: Liability component June 30, 2017 December 31, 2016 Principal $ $ Less: debt discount (1) ) ) Less: deferred financing(1) ) ) Net carrying value of the debt $ $ (1) |
Components of total interest expense recognized related to the Convertible Notes | Components (In thousands) Three Months Six Months Contractual interest expense $ $ Amortization of deferred financing Amortization of debt discount Total $ $ |
Stockholders' Equity (Tables)
Stockholders' Equity (Tables) | 6 Months Ended |
Jun. 30, 2017 | |
Stockholders' Equity | |
Schedule of fair value weighted-average assumptions | Three Months Six Months Ended 2017 2016 2017 2016 Expected stock price volatility % % % % Risk free interest rate % % % % Expected life of options (years) Expected annual dividend per share $ $ $ $ |
Summary of stock options outstanding | Number of Weighted Weighted Aggregate (in thousands) (in millions) Options outstanding, December 31, 2016 $ Granted $ Exercised ) $ Forfeited ) $ Options outstanding, June 30, 2017 $ 7.4 years $ Vested and unvested expected to vest, June 30, 2017 $ 7.3 years $ 57.2 Exercisable at June 30, 2017 $ 6.2 years $ 34.2 |
Summary of non-vested Restricted Stock Units activity | Number of Share Weighted Weighted Average Aggregate Intrinsic (in thousands) (in millions) Non-vested units as of December 31, 2016 $ Granted $ Vested ) $ Forfeited ) $ Non-vested units as of June 30, 2017 $ 2.9 years $ |
Summary of the equity-based compensation expense recognized in the statements of operations | The following table summarizes information related to compensation expense recognized in the statements of operations related to the equity awards (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2017 2016 2017 2016 Equity compensation expense recognized in: Research and development expense $ $ $ Selling, general and administrative expense Total equity compensation expense $ $ $ |
Assets and Liabilities Measur25
Assets and Liabilities Measured at Fair Value (Tables) | 6 Months Ended |
Jun. 30, 2017 | |
Summary of assets and liabilities subject to fair value measurements | A summary of the fair value of the Company’s recurring assets and liabilities aggregated by the level in the fair value hierarchy within which those measurements fall as of June 30, 2017 are identified in the following table (in thousands): Level 2 Total Assets: Commercial paper $ $ Corporate debt securities Money market funds $ $ Level 2 Level 3 Total Liabilities: Contingent consideration payable $ — $ $ Derivative liability — — — Deferred compensation plan liability — $ $ $ A summary of the fair value of the Company’s recurring assets and liabilities aggregated by the level in the fair value hierarchy within which those measurements fall as of December 31, 2016 are identified in the following table (in thousands): Level 2 Total Assets: Commercial paper $ $ Corporate debt securities Money market funds $ $ Level 2 Level 3 Total Liabilities: Contingent consideration payable $ — $ $ Derivative liability — Deferred compensation plan liability — $ $ $ |
Schedule of changes in contingent consideration payable | The following table shows the change in the balance of contingent consideration payable for the three and six months ended June 30, 2017 and 2016, respectively (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2017 2016 2017 2016 Balance, beginning of the period $ $ Payment of contingent consideration in cash ) ) ) ) Payment of contingent consideration in stock — ) — ) Unrealized change in fair value change during the period, included in Statement of Operations Balance, end of the period $ $ $ |
Scioderm | |
Schedule of significant unobservable inputs used in the valuation of the contingent consideration payable | Contingent Consideration Fair value as of Valuation Technique Unobservable Input Range Clinical and regulatory milestones $228.1 million Probability weighted discounted cash flow Discount rate 1.0%-1.3% Probability of achievement of milestones 66.5% -70.0% Projected year of payments 2017-2019 Revenue-based milestones $26.6 million Monte Carlo Revenue volatility 51% Probability of achievement of milestones 66.5% Discount rate 1.5%-2.4% Projected year of payments 2019-2035 |
Callidus | |
Schedule of significant unobservable inputs used in the valuation of the contingent consideration payable | Contingent Consideration Fair value as of Valuation Technique Unobservable Input Range Clinical and regulatory milestones $10.3 million Probability weighted discounted cash flow Discount rate 12.5% Probability of achievement of milestones 32.0%-45.0% Projected year of payments 2018-2022 |
Basic and Diluted Net Loss pe26
Basic and Diluted Net Loss per Common Share (Tables) | 6 Months Ended |
Jun. 30, 2017 | |
Basic and Diluted Net Loss per Common Share | |
Schedule of reconciliation of the numerator and denominator used in computing basic and diluted net loss per common share | The following table provides a reconciliation of the numerator and denominator used in computing basic and diluted net loss attributable to common stockholders per common share (in thousands except share amounts): (In thousands, except per share Three Months Ended June 30, Six Months Ended June 30, amounts) 2017 2016 2017 2016 Numerator: Net loss attributable to common stockholders $ ) $ ) $ ) $ ) Denominator: Weighted average common shares outstanding — basic and diluted |
Schedule of potential shares of common stock that were excluded from the computation as they were anti-dilutive using the treasury stock method | The table below presents potential shares of Common Stock that were excluded from the computation as they were anti-dilutive using the treasury stock method (in thousands): As of June 30, 2017 2016 Options to purchase common stock Convertible debt — Outstanding warrants, convertible to common stock Unvested restricted stock units Vested restricted stock units, unissued — Total number of potentially issuable shares |
Description of Business (Detail
Description of Business (Details) - USD ($) $ / shares in Units, $ in Thousands | Jul. 18, 2017 | Jul. 12, 2017 | Jun. 30, 2016 |
Corporate Information, Status of Operations and Management Plans | |||
Net proceeds from the issuance of common stock | $ 57,818 | ||
Subsequent event | Common Stock | |||
Corporate Information, Status of Operations and Management Plans | |||
Number of common stock issued from underwriting agreement | 21,122,449 | ||
Price per share of common stock issued (in dollars per share) | $ 12.25 | ||
Gross proceeds from issue of common stock before deducting underwriting discounts and commissions | $ 258,800 | ||
Net proceeds from the issuance of common stock | $ 243,200 |
Summary of Significant Accoun28
Summary of Significant Accounting Policies - Foreign Currency Transactions (Details) | 1 Months Ended |
Jun. 30, 2016item | |
Summary of Significant Accounting Policies | |
Number of forward contracts | 1 |
Acquisitions (Details)
Acquisitions (Details) - USD ($) $ / shares in Units, $ in Thousands | Jul. 05, 2016 | Sep. 30, 2015 | Apr. 30, 2017 | Apr. 30, 2016 | Jun. 30, 2017 | Mar. 31, 2017 | Jun. 30, 2017 | Jun. 30, 2016 | Dec. 31, 2016 |
Acquisitions | |||||||||
Common stock, par value (in dollars per share) | $ 0.01 | $ 0.01 | $ 0.01 | ||||||
Contingent consideration payable | $ 265,350 | $ 265,350 | $ 269,722 | ||||||
Contingent consideration payable, current portion | 46,188 | 46,188 | $ 56,101 | ||||||
Changes in fair value of contingent consideration payable | 5,628 | $ 13,338 | |||||||
Scioderm | |||||||||
Acquisitions | |||||||||
Initial amount to Effective Time Holders | $ 223,900 | ||||||||
Initial amount cash payment excluding Series B Preferred | 141,100 | ||||||||
Initial amount paid in shares of Common Stock | $ 82,800 | ||||||||
Priority review voucher transfer years | 1 year | ||||||||
Payment to be made if Priority Review Voucher is obtained and used | $ 100,000 | ||||||||
Contingent consideration payable | 259,000 | 254,700 | 254,700 | ||||||
Enrollment rate (as a percent) | 100.00% | ||||||||
Milestone payment | $ 10,000 | ||||||||
Contingent consideration payable, current portion | 46,200 | 46,200 | |||||||
Scioderm | Changes in fair value of contingent consideration payable | |||||||||
Acquisitions | |||||||||
Changes in fair value of contingent consideration payable | 700 | ||||||||
Scioderm | Maximum | |||||||||
Acquisitions | |||||||||
Priority Review Voucher sale proceeds shared | $ 100,000 | ||||||||
Priority Review Voucher sale proceeds shared (as a percent) | 50.00% | ||||||||
Scioderm | Amicus | Common Stock | |||||||||
Acquisitions | |||||||||
Consideration paid in common stock | 5,900,000 | ||||||||
MiaMed Inc | |||||||||
Acquisitions | |||||||||
Asset acquisition, total consideration, stock and cash | $ 6,500 | ||||||||
Asset acquisition, cash consideration paid | 1,800 | ||||||||
Asset acquisition, potential aggregate deal value | 89,500 | ||||||||
Charges to research expense for stock issued in asset acquisition | $ 6,500 | ||||||||
MiaMed Inc | Amicus | Common Stock | |||||||||
Acquisitions | |||||||||
Asset acquisition, consideration paid in common stock | 825,603 | ||||||||
Common stock, par value (in dollars per share) | $ 0.01 | ||||||||
Clinical, Regulatory and Commercial milestones | MiaMed Inc | Maximum | |||||||||
Acquisitions | |||||||||
Contingent consideration payable upon achievement of milestones | $ 83,000 | ||||||||
Clinical and Regulatory Approval milestones | Scioderm | |||||||||
Acquisitions | |||||||||
Contingent consideration payable | 228,100 | 228,100 | |||||||
Clinical and Regulatory Approval milestones | Scioderm | Minimum | |||||||||
Acquisitions | |||||||||
Discount rate (as a percent) | 0.40% | ||||||||
Clinical and Regulatory Approval milestones | Scioderm | Maximum | |||||||||
Acquisitions | |||||||||
Upfront cash payments | $ 361,000 | $ 361,000 | |||||||
Discount rate (as a percent) | 1.10% | ||||||||
Clinical and Regulatory Approval milestones | MiaMed Inc | Maximum | |||||||||
Acquisitions | |||||||||
Contingent consideration payable upon achievement of milestones | $ 83,000 | ||||||||
Revenue-based milestones | Scioderm | |||||||||
Acquisitions | |||||||||
Upfront equity payments | $ 257,000 | ||||||||
Contingent consideration payable | $ 26,600 | 26,600 | |||||||
Revenue-based milestones | Scioderm | Minimum | |||||||||
Acquisitions | |||||||||
Discount rate (as a percent) | 1.00% | ||||||||
Revenue-based milestones | Scioderm | Maximum | |||||||||
Acquisitions | |||||||||
Upfront equity payments | $ 257,000 | ||||||||
Discount rate (as a percent) | 2.20% | ||||||||
Clinical milestone | Scioderm | Maximum | |||||||||
Acquisitions | |||||||||
Upfront cash payments | 81,000 | ||||||||
Regulatory Approval milestone | Scioderm | Maximum | |||||||||
Acquisitions | |||||||||
Upfront cash payments | $ 280,000 |
Goodwill and IPR&D - Goodwill (
Goodwill and IPR&D - Goodwill (Details) $ in Thousands | 6 Months Ended |
Jun. 30, 2017USD ($) | |
Changes in goodwill | |
Balance at beginning of the period | $ 197,797 |
Balance at end of the period | 197,797 |
Business Acquisitions | |
Changes in goodwill | |
Balance at beginning of the period | 197,800 |
Change in goodwill | 0 |
Balance at end of the period | $ 197,800 |
Goodwill and IPR&D - IPR&D (Det
Goodwill and IPR&D - IPR&D (Details) - IPR&D $ in Millions | 6 Months Ended |
Jun. 30, 2017USD ($) | |
Changes in IPR&D | |
Balance at beginning of the period | $ 486.7 |
Change in IPR&D | 0 |
Balance at end of the period | 486.7 |
Business Acquisitions | |
Changes in IPR&D | |
Balance at end of the period | $ 486.7 |
Cash, Money Market Funds and 32
Cash, Money Market Funds and Marketable Securities (Details) - USD ($) $ in Thousands | 6 Months Ended | 12 Months Ended | ||
Jun. 30, 2017 | Dec. 31, 2016 | Jun. 30, 2016 | Dec. 31, 2015 | |
Cash, Money Market Funds, and Marketable Securities | ||||
Cash and cash equivalents, Amortized Cost | $ 37,394 | $ 187,026 | $ 63,656 | $ 69,485 |
Cash and cash equivalents, Fair Value | 37,394 | 187,026 | ||
Marketable securities, Amortized Cost | 189,807 | 143,222 | ||
Gross Unrealized Gain | 66 | 134 | ||
Gross Unrealized Loss | (35) | (31) | ||
Marketable securities, Fair Value | 189,838 | 143,325 | ||
Cash and marketable securities, Amortized Cost | 227,201 | 330,248 | ||
Cash and marketable securities, Fair Value | 227,232 | 330,351 | ||
Available-for-sale investments | ||||
Realized gain (loss) on securities available-for-sale | 0 | 0 | ||
Fair value of available for sale securities in unrealized loss positions | 93,700 | 58,700 | ||
Other current liabilities | ||||
Cash, Money Market Funds, and Marketable Securities | ||||
Derivative liabilities | 0 | 300 | ||
Other current liabilities | Foreign exchange forward contract | Not designated | ||||
Cash, Money Market Funds, and Marketable Securities | ||||
Derivative liabilities | 0 | |||
Other expense | Foreign exchange forward contract | Not designated | ||||
Cash, Money Market Funds, and Marketable Securities | ||||
Gain (loss) on derivative instruments | 200 | |||
Corporate debt securities | ||||
Cash, Money Market Funds, and Marketable Securities | ||||
Marketable securities, Amortized Cost | 108,683 | 74,564 | ||
Gross Unrealized Gain | 1 | 2 | ||
Gross Unrealized Loss | (35) | (31) | ||
Marketable securities, Fair Value | 108,649 | 74,535 | ||
Commercial paper | ||||
Cash, Money Market Funds, and Marketable Securities | ||||
Marketable securities, Amortized Cost | 80,724 | 68,258 | ||
Gross Unrealized Gain | 65 | 132 | ||
Marketable securities, Fair Value | 80,789 | 68,390 | ||
Money market | ||||
Cash, Money Market Funds, and Marketable Securities | ||||
Marketable securities, Amortized Cost | 350 | 350 | ||
Marketable securities, Fair Value | 350 | 350 | ||
Certificate of deposit | ||||
Cash, Money Market Funds, and Marketable Securities | ||||
Marketable securities, Amortized Cost | 50 | 50 | ||
Marketable securities, Fair Value | $ 50 | $ 50 |
Inventories (Details)
Inventories (Details) - USD ($) $ in Thousands | 6 Months Ended | |
Jun. 30, 2017 | Dec. 31, 2016 | |
Inventories | ||
Work-in-process | $ 3,758 | $ 3,308 |
Finished goods | 190 | 108 |
Total inventories | 3,948 | $ 3,416 |
Inventory write-downs | $ 0 |
Debt Instruments - Convertible
Debt Instruments - Convertible Debt (Details) | Dec. 21, 2016USD ($)$ / sharesshares | Dec. 15, 2016$ / item | Jun. 30, 2017USD ($) | Jun. 30, 2017USD ($) | Dec. 31, 2016USD ($) |
Convertible Debt | |||||
Debt instrument term | 7 years | ||||
Equity component of the Convertible Notes | $ 88,300,000 | ||||
Deferred tax liability in relation to the Convertible Notes | 29,800,000 | ||||
Convertible Notes | 2016 Convertible Notes | |||||
Convertible Debt | |||||
Aggregate principle amount | $ 250,000,000 | ||||
Net proceeds after deducting fees and estimated expenses | 243,100,000 | ||||
Net proceeds from convertible notes to pay capped call transactions | $ 13,500,000 | ||||
Shares of common stock issued per increment of note principal | shares | 40,849,675 | ||||
Debt conversion ratio (in shares) | 0.1633987 | ||||
Increment used for debt conversion | $ 1,000 | ||||
Conversion price (in dollars per share) | $ / shares | $ 6.12 | ||||
Maximum calendar days allowed to holders of common stock rights options or warrants to purchase of common stock | 60 days | ||||
Trading days for price per share based on last reported sale price | 10 days | ||||
Minimum percentage of per share value of last reported sale price of common stock | 10.00% | ||||
Convertible notes issuance costs | $ 7,500,000 | ||||
Convertible notes issuance cost paid | $ 6,900,000 | ||||
Liability components of convertible notes | |||||
Principle | $ 250,000,000 | $ 250,000,000 | 250,000,000 | ||
Less: debt discount | (86,314,000) | (86,314,000) | (90,807,000) | ||
Less: deferred financing | (4,515,000) | (4,515,000) | (4,729,000) | ||
Net carrying value of debt | 159,171,000 | 159,171,000 | $ 154,464,000 | ||
Fair value of the debt | 445,900,000 | 445,900,000 | |||
Interest Expense, Debt [Abstract] | |||||
Contractual interest expense | 1,867,000 | 3,754,000 | |||
Amortization of deferred financing | 80,000 | 222,000 | |||
Amortization of debt discount | 2,232,000 | 4,493,000 | |||
Total interest expense | $ 4,179,000 | $ 8,469,000 | |||
Effective interest rate of the liability component | 10.85% | 10.85% | |||
Initial cap price | $ / item | 7.20 | ||||
Capped call premium on closing price | 50.00% | ||||
Convertible Notes | 2016 Convertible Notes | Convertible Notes, condition 1 | |||||
Convertible Debt | |||||
Threshold consecutive trading days | 30 days | ||||
Threshold percentage | 130.00% | ||||
Convertible Notes | 2016 Convertible Notes | Convertible Notes, condition 1 | Minimum | |||||
Convertible Debt | |||||
Threshold trading days | 20 days | ||||
Convertible Notes | 2016 Convertible Notes | Convertible Notes, condition 2 | |||||
Convertible Debt | |||||
Increment used for debt conversion | $ 1,000 | ||||
Threshold trading days | 5 days | ||||
Threshold consecutive trading days | 5 days | ||||
Maximum threshold percentage | 98.00% | ||||
Over-allotment Option | Private Placement Purchase Agreement | Convertible Notes | 2016 Convertible Notes | |||||
Convertible Debt | |||||
Aggregate principle amount | $ 25,000,000 |
Stockholders' Equity - Common S
Stockholders' Equity - Common Stock and Warrants (Details) | Dec. 21, 2016USD ($)$ / shares | Jun. 30, 2017itemshares | Dec. 31, 2016shares |
Convertible Debt | |||
Authorized number of shares of common stock | shares | 250,000,000 | 250,000,000 | |
Voting right for each share held, number | item | 1 | ||
2016 Convertible Notes | Convertible Notes | |||
Convertible Debt | |||
Aggregate principle amount | $ 250,000,000 | ||
Debt conversion ratio (in shares) | 0.1633987 | ||
Increment used for debt conversion | $ 1,000 | ||
Conversion price (in dollars per share) | $ / shares | $ 6.12 | ||
2016 Convertible Notes | Convertible Notes | Common Stock | |||
Convertible Debt | |||
Debt conversion ratio (in shares) | 0.1633987 | ||
Increment used for debt conversion | $ 1,000 | ||
Conversion price (in dollars per share) | $ / shares | $ 6.12 |
Stockholders' Equity - Nonquali
Stockholders' Equity - Nonqualified Cash and Equity Incentive Plans (Details) - USD ($) | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2017 | Jun. 30, 2016 | Jun. 30, 2017 | Jun. 30, 2016 | |
Common stock options | ||||
Fair value weighted-average assumptions: | ||||
Expected stock price volatility (as a percent) | 82.70% | 81.30% | 83.20% | 81.20% |
Risk free interest rate (as a percent) | 1.90% | 1.30% | 2.00% | 1.70% |
Expected life of options | 6 years 3 months | 6 years 3 months | 6 years 3 months | 6 years 3 months |
Expected annual dividend per share (in dollars per share) | $ 0 | $ 0 | $ 0 | $ 0 |
Number of Shares | ||||
Balance at the beginning of the period (in shares) | 15,497,500 | |||
Options granted (in shares) | 2,889,500 | |||
Options exercised (in shares) | (464,400) | |||
Options forfeited (in shares) | (648,000) | |||
Balance at the end of the period (in shares) | 17,274,600 | 17,274,600 | ||
Vested and unvested expected to vest as of the end of the period (in shares) | 16,249,700 | 16,249,700 | ||
Exercisable at the end of the period (in shares) | 8,931,200 | 8,931,200 | ||
Weighted Average Exercise Price | ||||
Balance at the beginning of the period (in dollars per share) | $ 7.37 | |||
Options granted (in dollars per share) | 5.44 | |||
Options exercised (in dollars per share) | 3.82 | |||
Options forfeited (in dollars per share) | 11.06 | |||
Balance at the end of the period (in dollars per share) | $ 7 | 7 | ||
Vested and unvested expected to vest as of the end of the period (in dollars per share) | 7 | 7 | ||
Exercisable at the end of the period (in dollars per share) | $ 6.69 | $ 6.69 | ||
Weighted Average Remaining Contractual Life | ||||
Balance at the end of the period | 7 years 4 months 24 days | |||
Vested and unvested expected to vest at the end of the period | 7 years 3 months 18 days | |||
Exercisable at the end of the period | 6 years 2 months 12 days | |||
Aggregate Intrinsic Value | ||||
Aggregate intrinsic value of options outstanding (in dollars) | $ 60,600 | $ 60,600 | ||
Aggregate intrinsic value of options vested and unvested expected to vest (in dollars) | 57,200 | 57,200 | ||
Aggregate intrinsic value of options exercisable (in dollars) | 34,200 | 34,200 | ||
Total unrecognized compensation cost related to non-vested stock options granted (in dollars) | $ 34,700,000 | $ 34,700,000 | ||
Period of recognition unrecognized compensation costs (in years) | 2 years 7 months 6 days | |||
Restricted stock units (RSUs) | Amended and Restated 2007 Equity Incentive Plan | ||||
Aggregate Intrinsic Value | ||||
Estimated fair value (in dollars per share) | $ 5.69 | |||
Period of recognition unrecognized compensation costs (in years) | 3 years | |||
Restricted Stock Units, Number of Shares | ||||
Non-vested units as of the beginning of the period (in shares) | 744,400 | |||
Granted (in shares) | 2,348,700 | |||
Vested (in shares) | 203,106 | |||
Forfeited (in shares) | (63,800) | |||
Non-vested units as of the end of the period (in shares) | 2,826,200 | 2,826,200 | ||
Weighted Average Grant Date Fair Value | ||||
Non-vested units as of the beginning of the period (in dollars per share) | $ 7.86 | |||
Granted (in dollars per share) | 5.69 | |||
Vested (in dollars per share) | 8.40 | |||
Forfeited (in dollars per share) | 7.19 | |||
Non-vested units as of the end of the period (in dollars per share) | $ 6.04 | $ 6.04 | ||
Weighted Average Remaining Years | ||||
Non-vested units as of the end of the period | 2 years 10 months 24 days | |||
Aggregate Intrinsic Value | ||||
Non-vested units as of the end of the period (in dollars) | $ 28,500,000 | $ 28,500,000 | ||
Unrecognized compensation cost related to unvested RSU's (in dollars) | $ 12,400,000 | $ 12,400,000 | ||
Clinical milestone | Restricted stock units (RSUs) | Amended and Restated 2007 Equity Incentive Plan | ||||
Aggregate Intrinsic Value | ||||
Vesting period | 3 years | |||
Restricted Stock Units, Number of Shares | ||||
Granted (in shares) | 401,413 | |||
Executive Officers | Market Performance-based Restricted Stock Units (MPRSUs) | Amended and Restated 2007 Equity Incentive Plan | ||||
Aggregate Intrinsic Value | ||||
Vesting period | 3 years | |||
Estimated fair value (in dollars per share) | $ 8.08 | |||
Restricted Stock Units, Number of Shares | ||||
Granted (in shares) | 401,413 | |||
Weighted Average Grant Date Fair Value | ||||
Granted (in dollars per share) | $ 8.08 | |||
Executive Officers | Market Performance-based Restricted Stock Units (MPRSUs) | Amended and Restated 2007 Equity Incentive Plan | Cliff Vesting | ||||
Aggregate Intrinsic Value | ||||
Vesting period | 3 years | |||
Maximum | Executive Officers | Market Performance-based Restricted Stock Units (MPRSUs) | Amended and Restated 2007 Equity Incentive Plan | ||||
Fair value weighted-average assumptions: | ||||
Vesting percentage | 200.00% | |||
Number of Shares | ||||
Exercisable at the end of the period (in shares) | 802,826 | 802,826 |
Stockholders' Equity - Compensa
Stockholders' Equity - Compensation Expense (Details) - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2017 | Jun. 30, 2016 | Jun. 30, 2017 | Jun. 30, 2016 | |
Equity compensation expense | ||||
Total equity compensation expense | $ 5,537 | $ 4,466 | $ 11,567 | $ 8,748 |
Research and development expense | ||||
Equity compensation expense | ||||
Total equity compensation expense | 2,313 | 1,966 | 5,066 | 3,902 |
Selling, general and administrative expenses | ||||
Equity compensation expense | ||||
Total equity compensation expense | $ 3,224 | $ 2,500 | $ 6,501 | $ 4,846 |
Assets and Liabilities Measur38
Assets and Liabilities Measured at Fair Value (Details) - USD ($) $ in Thousands | Jul. 05, 2016 | Sep. 30, 2015 | Jun. 30, 2017 | Jun. 30, 2016 | Jun. 30, 2017 | Jun. 30, 2016 | Dec. 31, 2016 |
Financial assets and liabilities subject to fair value measurements | |||||||
Transfer of assets from Level 1 to Level 2 | $ 0 | $ 0 | |||||
Transfer of assets from Level 2 to Level 1 | 0 | 0 | |||||
Assets: | |||||||
Fair value of assets | 191,758 | 191,758 | $ 144,754 | ||||
Liabilities: | |||||||
Contingent consideration payable | 265,350 | 265,350 | 269,722 | ||||
Derivative liability | 265 | ||||||
Deferred compensation plan liability | 1,994 | 1,994 | 1,479 | ||||
Fair value of liabilities | 267,344 | 267,344 | 271,466 | ||||
Contingent consideration payable | 265,350 | 265,350 | 269,722 | ||||
Contingent consideration payable | |||||||
Balance, beginning of the period | 274,300 | $ 277,229 | 269,722 | $ 274,077 | |||
Payment of contingent consideration in cash | (10,000) | (5,000) | (10,000) | (5,000) | |||
Payment of contingent consideration in stock | (6,115) | (6,115) | |||||
Unrealized change in fair value change during the period, included in Statement of Operations | 1,050 | 10,186 | 5,628 | 13,338 | |||
Balance, end of the period | 265,350 | $ 276,300 | 265,350 | $ 276,300 | |||
Other current liabilities | |||||||
Foreign Currency Exchange Rate Exposure | |||||||
Derivative liabilities | 0 | 0 | 300 | ||||
Scioderm | |||||||
Liabilities: | |||||||
Contingent consideration payable | $ 259,000 | 254,700 | 254,700 | ||||
Contingent consideration payable | $ 259,000 | 254,700 | 254,700 | ||||
MiaMed Inc | |||||||
Contingent consideration payable | |||||||
Asset acquisition, potential aggregate deal value | $ 89,500 | ||||||
Clinical and Regulatory Approval milestones | Scioderm | |||||||
Liabilities: | |||||||
Contingent consideration payable | 228,100 | 228,100 | |||||
Contingent consideration payable | 228,100 | 228,100 | |||||
Revenue-based milestones | Scioderm | |||||||
Liabilities: | |||||||
Contingent consideration payable | 26,600 | 26,600 | |||||
Contingent consideration payable | 26,600 | 26,600 | |||||
Minimum | Clinical and Regulatory Approval milestones | Scioderm | |||||||
Liabilities: | |||||||
Discount rate (as a percent) | 0.40% | ||||||
Minimum | Revenue-based milestones | Scioderm | |||||||
Liabilities: | |||||||
Discount rate (as a percent) | 1.00% | ||||||
Maximum | Clinical and Regulatory Approval milestones | Scioderm | |||||||
Liabilities: | |||||||
Discount rate (as a percent) | 1.10% | ||||||
Maximum | Clinical and Regulatory Approval milestones | MiaMed Inc | |||||||
Contingent consideration payable | |||||||
Contingent consideration payable upon achievement of milestones | 83,000 | ||||||
Maximum | Revenue-based milestones | Scioderm | |||||||
Liabilities: | |||||||
Discount rate (as a percent) | 2.20% | ||||||
Maximum | Clinical, Regulatory and Commercial milestones | MiaMed Inc | |||||||
Contingent consideration payable | |||||||
Contingent consideration payable upon achievement of milestones | $ 83,000 | ||||||
ATB200 Pompe program | Clinical and Regulatory Approval milestones | Callidus | |||||||
Liabilities: | |||||||
Contingent consideration payable | 10,300 | 10,300 | |||||
Contingent consideration payable | 10,300 | 10,300 | |||||
Commercial paper | |||||||
Assets: | |||||||
Fair value of assets | 80,789 | 80,789 | 68,390 | ||||
Corporate debt securities | |||||||
Assets: | |||||||
Fair value of assets | 108,649 | 108,649 | 74,535 | ||||
Money market | |||||||
Assets: | |||||||
Fair value of assets | 2,320 | 2,320 | 1,829 | ||||
Level 2 | |||||||
Assets: | |||||||
Fair value of assets | 191,758 | 191,758 | 144,754 | ||||
Liabilities: | |||||||
Derivative liability | 265 | ||||||
Deferred compensation plan liability | 1,994 | 1,994 | 1,479 | ||||
Fair value of liabilities | 1,994 | 1,994 | 1,744 | ||||
Level 2 | Commercial paper | |||||||
Assets: | |||||||
Fair value of assets | 80,789 | 80,789 | 68,390 | ||||
Level 2 | Corporate debt securities | |||||||
Assets: | |||||||
Fair value of assets | 108,649 | 108,649 | 74,535 | ||||
Level 2 | Money market | |||||||
Assets: | |||||||
Fair value of assets | 2,320 | 2,320 | 1,829 | ||||
Level 3 | |||||||
Liabilities: | |||||||
Contingent consideration payable | 265,350 | 265,350 | 269,722 | ||||
Fair value of liabilities | 265,350 | 265,350 | 269,722 | ||||
Contingent consideration payable | $ 265,350 | $ 265,350 | $ 269,722 | ||||
Level 3 | Revenue-based milestones | Monte Carlo | Scioderm | |||||||
Liabilities: | |||||||
Probability of achievement of milestones (as a percent) | 66.50% | ||||||
Revenue volatility (as a percent) | 51.00% | ||||||
Level 3 | Minimum | Clinical and Regulatory Approval milestones | Probability weighted discounted cash flow | Scioderm | |||||||
Liabilities: | |||||||
Discount rate (as a percent) | 1.00% | ||||||
Probability of achievement of milestones (as a percent) | 66.50% | ||||||
Level 3 | Minimum | Revenue-based milestones | Monte Carlo | Scioderm | |||||||
Liabilities: | |||||||
Discount rate (as a percent) | 1.50% | ||||||
Level 3 | Maximum | Clinical and Regulatory Approval milestones | Probability weighted discounted cash flow | Scioderm | |||||||
Liabilities: | |||||||
Discount rate (as a percent) | 1.30% | ||||||
Probability of achievement of milestones (as a percent) | 70.00% | ||||||
Level 3 | Maximum | Revenue-based milestones | Monte Carlo | Scioderm | |||||||
Liabilities: | |||||||
Discount rate (as a percent) | 2.40% | ||||||
Level 3 | ATB200 Pompe program | Clinical and Regulatory Approval milestones | Probability weighted discounted cash flow | Callidus | |||||||
Liabilities: | |||||||
Discount rate (as a percent) | 12.50% | ||||||
Level 3 | ATB200 Pompe program | Minimum | Clinical and Regulatory Approval milestones | Probability weighted discounted cash flow | Callidus | |||||||
Liabilities: | |||||||
Probability of achievement of milestones (as a percent) | 32.00% | ||||||
Level 3 | ATB200 Pompe program | Maximum | Clinical and Regulatory Approval milestones | Probability weighted discounted cash flow | Callidus | |||||||
Liabilities: | |||||||
Probability of achievement of milestones (as a percent) | 45.00% |
Basic and Diluted Net Loss pe39
Basic and Diluted Net Loss per Common Share (Details) - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2017 | Jun. 30, 2016 | Jun. 30, 2017 | Jun. 30, 2016 | |
Numerator: | ||||
Net loss attributable to common stockholders | $ (48,136) | $ (51,050) | $ (103,129) | $ (94,741) |
Denominator: | ||||
Weighted average common shares outstanding - basic and diluted | 143,000,718 | 129,122,175 | 142,886,614 | 127,160,943 |
Antidilutive securities excluded from computation of diluted earnings per share (in shares) | 64,111,000 | 17,703,000 | ||
Common stock options | ||||
Denominator: | ||||
Antidilutive securities excluded from computation of diluted earnings per share (in shares) | 17,275,000 | 14,271,000 | ||
Convertible debt | ||||
Denominator: | ||||
Antidilutive securities excluded from computation of diluted earnings per share (in shares) | 40,850,000 | |||
Warrants | ||||
Denominator: | ||||
Antidilutive securities excluded from computation of diluted earnings per share (in shares) | 3,110,000 | 3,110,000 | ||
Restricted stock units (RSUs) | ||||
Denominator: | ||||
Antidilutive securities excluded from computation of diluted earnings per share (in shares) | 2,826,000 | 322,000 | ||
Vested restricted stock units, unissued | ||||
Denominator: | ||||
Antidilutive securities excluded from computation of diluted earnings per share (in shares) | 50,000 |
Commitments and Contingencies (
Commitments and Contingencies (Details) | Jun. 30, 2017lawsuit |
Commitments and Contingencies | |
Number of purported securities class action lawsuits | 3 |
Number of purported securities class action lawsuits naming additional company officers as defendants | 1 |
Subsequent Events (Details)
Subsequent Events (Details) - USD ($) $ / shares in Units, $ in Thousands | Jul. 18, 2017 | Jul. 12, 2017 | Jun. 30, 2016 |
Subsequent Events | |||
Net proceeds from the issuance of common stock | $ 57,818 | ||
Subsequent event | Common Stock | |||
Subsequent Events | |||
Number of common stock issued from underwriting agreement | 21,122,449 | ||
Price per share of common stock issued (in dollars per share) | $ 12.25 | ||
Gross proceeds from issue of common stock before deducting underwriting discounts and commissions | $ 258,800 | ||
Net proceeds from the issuance of common stock | $ 243,200 |